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SUMMARY 
 
Human natural killer (NK) cells constitute an important arm of the innate immune 
system, which participates in protection against viral infections and elimination of 
malignant diseases. They carry variegated receptors on their surface, with killer 
cell immunoglobulin-like receptors (KIR) playing a main role in the regulation of 
their activity. The KIR family involves inhibitory and activating members.  The 
former interact with HLA class I molecules. Decreased or absent HLA class I 
expression abrogates inhibition. Binding specificities of activating members are 
mostly unknown (except for KIR2DS1 and KIR2DS4). However, there are 
abundant clinical data indirectly indicating a role for activating KIRs in antiviral and 
antileukemic NK cell activity.  
Our studies aimed to dissect the role of activating KIRs in antiviral and 
antileukemic activity, and to assess their potential diagnostic and 
immunotherapeutic value. They were performed on the level of genotype 
associations, by evaluation of KIR repertoire after infectious challenge, and by 
assessing functionality in vitro. 
In the first part, we searched for predictive markers allowing identification of 
HIV-infected patients able to control viral replication after structured treatment 
interruption (STI). Candidate factors were genes known to associate with HIV viral 
load in untreated patients. Therefore we studied the correlation of KIR3DL1 and its 
ligand HLA-Bw4, but also KIR3DS1 and SNPs (HLA-C-35 and HCP5) with the 
evolution of viral load after STI. Only the presence of HLA-Bw4 was significantly 
associated with control of viral replication. However, the predictive power of this 
genotype was modest.  
In further studies we investigated differences of KIR expression in resting 
NK cells in CMV-seronegative and –seropositive individuals, and changes in KIR 
repertoire after challenging NK cells with CMV-infected fibroblasts in vitro. While 
resting NK cells did not differ in their KIR expression, in vitro exposure to CMV 
caused expansion of KIR2DL1, KIR2DL3, and KIR3DS1 uniquely in CMV 
seropositive donors. For KIR2DL1 and KIR2DL3, expansion occurred only in 
patients carrying the respective KIR ligands. The expansion of KIR3DS1 positive 
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NK cells confirmed participation of the telomeric part of KIR haplotype B in anti-
CMV activity, but was unrelated to presence of its putative ligand - HLA-Bw4. 
These results encouraged us to broader studies of the function of activating 
KIRs. We therefore expressed a selected panel of activating KIRs separately in 
the NK cell line NKL, generated soluble forms of each activating KIR by 
connecting their extracellular domains to IgG-Fc fragments, and using these 
reagents to control specificity, we established a novel staining method for 
KIR2DS5 using commercially available antibodies. Despite functionality of 
expressed receptors against a mouse cell line, the presence of the KIR for which 
some HLA class I ligands are known did produce no detectable enhancement of 
cytotoxicity in cytotoxicity experiments against 721.221 cells transfected with these 
HLA class I ligands. Soluble forms of KIR-Fc were used to screen a panel of 
leukemic cell lines for the presence of potential KIR ligands by flow cytometry. The 
HLA class I deficient cell line K562 bound KIR2DS3-Fc and KIR2DS5-Fc, and the 
HLA class I expressing cell lines HEL and Namalwa bound also both these KIR-Fc 
on their surfaces. The binding of the latter was blockable by anti-HLA antibodies 
and - based on the HLA configuration of both cell lines - was independent on HLA-
C. The participation of the KIR2DS5 receptor in killing of K562 cells by primary NK 
cells was indirectly confirmed, but requires a further investigation. 
Collectively, these data suggest a potential antiviral effect of KIR3DS1 and 
a possible antileukemic effect of KIR2DS5. Their presence could predict individual 
immune responses, and taking into account their function could be beneficial in 
immunotherapeutic settings.    
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INTRODUCTION 
 
Overview 
 
Natural killer cells constitute a subset of lymphocytes being able to recognize 
directly and eliminate virus-infected cells and malignant cells without any 
additional priming. Their function is governed by many receptors present on their 
surface amongst which the KIR family is one of the most important. These 
receptors are expressed on NK cells in a clonal manner and are divided into 
inhibitory and activating members. The main difference between them is the 
structure of their intracellular domain, which is long and carrying ITIM domains in 
the former and short, associated with DAP12 adaptor protein ITAM domains in the 
latter. The extracellular part of KIRs decides on their binding specificities. The 
inhibitory members bind HLA-C molecules and the binding preference of activating 
KIRs is except from KIR2DS1, sharing the specificity of its inhibitory counterpart, 
not known. In contrast to T-lymphocytes becoming unresponsive in the absence or 
downregulation of HLA class I molecules, that change activates NK cells due to 
abolishment of inhibition. The additional factor triggering them could be 
substitution in peptide repertoire in HLA-context that decreases binding affinity of 
inhibitory KIRs or appearance of a ligand bound by an activating KIR. The result of 
NK cells activation is their degranulation and release of perforin and granzyme 
elucidating a cytotoxic effect on neighboring target cells, but also the production of 
immunomodulating cytokines. Genes responsible for KIRs are grouped in 
haplotypes and depending on presence of only one or more activating KIRs are 
divided into haplotype A and B respectively. The individuals carrying the latter 
were shown to have advantage in terms of antiviral protection and also their bone 
marrow exerted better antileukemic effect if transplanted to patients. Therefore, 
family of KIRs and especially the activating members become a subject of 
numerous studies concerning their immunotherapeutic and diagnostic potential.  
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Natural killer cells – historical view and general characteristics  
 
A new lymphocyte subset with particular features 
 
Natural killer cells were discovered in 1975 as particular lymphocytes, devoid of 
markers typical for B- and T-cells, and able to recognize and rapidly kill mouse T-
cell lymphoma cells without prior stimulation in vitro by unknown mechanisms [1, 
2]. Research during the following decade revealed more about human NK cell 
features, and they were therefore classified as a distinct subset of non-adherent, 
non-phagocytic, large, granular lymphocytes (LGL), comprising 10-15% of 
circulating lymphocytes. It was noted that, unlike T-lymphocytes, they neither 
express T-cell receptors or co-receptors (CD3), and hence their mechanism of 
target cell recognition must be different. The early characterization of NK cells 
indicated surface markers of which Fc-gamma receptor (CD16) and neural cell-
adhesion molecule (NCAM or CD56) are the most important. Nowadays for their 
identification the CD3(-), CD16(+) and CD56(+) antigens are mainly used. The 
expression levels of CD16 and CD56 differ among NK cells. They are therefore 
classified into two groups: CD56brightCD16+ and CD56dimCD16-. The former are 
presumably precursors of the latter, and the two subsets seem to play different 
roles in innate immunity. It also emerged that NK cells are able to spontaneously 
kill virus-infected cells, leaving uninfected cells untouched. This was demonstrated 
in mice, where transplantation of bone marrow from virus-resistant mouse strains 
to lethally irradiated virus-sensitive individuals conferred resistance against 
cytomegalovirus (CMV). Their antiviral role was confirmed in a human adolescent 
with NK cell deficiency, who was susceptible to severe viral infections [3]. 
Additionally, NK cells are able to kill a wide spectrum of pathogens in vitro. They 
combat gram-positive and gram-negative bacteria, Cryptococcus neoformans, 
Trypanosoma cruzi and Toxoplasma gondii [4, 5]. 
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Introduction of the “missing-self” theory and discovery of KIR 
 
Further investigations concerning the mode of activation of NK cells introduced the 
“missing-self” hypothesis. It was demonstrated using YAC-1 lymphoma cells that 
malignant cells with either downregulated or defective expression of MHC class I 
molecules are more sensitive to killing by NK cells. Similarly, F1 mice hybrids 
reject parental (MHC-mismatched) hematopoietic cells (hybrid resistance) [6]. This 
rejection is dependent on the absence of self-MHC antigens [7, 8]. In the early 
1990s, research provided more information about the mechanism underlying the 
recognition by NK cells of “non-self” or rather of lack of “self” antigens. NK cell 
clones used for immunizing mice delivered a panel of antibodies directed against 
NK cell surface proteins. One of those antibodies (GL183) not only divided NK 
cells into subtypes, but also pointed to interesting functions of its cognate ligand 
protein. NK cells carrying that antigen, a 58kDa protein, were less efficient in killing 
some tumor target cells (e.g. IGROV I). Addition of the GL183 mAb to NK cells 
increased the cytolytic activity against a panel of human tumor cells significantly. 
Based on that, the molecule recognized by GL183 was considered a regulatory 
molecule [9]. Similarly, in mice, NK cells expressing Ly49 receptors (the accepted 
equivalent of the KIR family in mice) exhibited reduced killing of tumor target cells 
possessing H-2d or H-2k MHC class I molecules on their surface [10]. Soon 
thereafter, another protein recognized by the EB6 antibody and with similar 
characteristics and molecular mass as the antigen recognized by GL183 was 
discovered [11]. Based on the presence or absence of these two antigens, human 
NK cells were divided into four subsets, differing in their capability to kill a variety 
of tumor cell lines (e.g. U937, A549, M14 and IGROV-1). Studies of genetic factors 
in humans and mice demonstrated the linkage of resistance of certain tumor cell 
lines to NK cell killing to the MHC locus [12, 13]. It was therefore hypothesized and 
then confirmed that MHC class I molecules (HLA-C) are ligands for receptors 
recognized by the GL183 and EB6 antibodies [14]. Later, both proteins were 
defined as receptors providing inhibitory function. Studying heterogeneity in HLA 
recognition of NK cells, another receptor called NKB1 was discovered by the DX9 
antibody and proved to bind ligands of the HLA-B group [15]. It became clear that 
receptors in both species interact with MHC class I molecules, getting educated or 
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licensed and drive the recognition of “self” from “non-self” antigens. The lack of 
their own cognate ligands during development causes anergy of KIR-expressing 
NK cell through a mechanism called ‘licensing’ [16]. Further investigations 
revealed the existence of activating counterparts [17]. Cloning of the newly 
discovered molecules showed their immunoglobulin-like structure, providing the 
reason for their name: killer cell immunoglobulin-like receptors (KIR), and also 
demonstrated diversity in their extra- and intracellular structure [18]. In the next 
few years, all KIR were identified and their coding genes, located in chromosome 
19q13.4 in a region named leukocyte receptor complex (LCR) became known [19]. 
Similarly to HLA-haplotypes, KIR-haplotypes constituting different combinations of 
KIR genes were defined [20]. KIR family coexists, however, with many other 
receptors on the surface of NK cells, by which their function is regulated.  
 
NK cells exhibit variegated functionality 
 
NK cell function is regulated by signals delivered from their repertoire of inhibitory 
and activating receptors [21]. Moreover, NK cell response can be also modified by 
cytokine stimulation (IL-2, IL-12, IL-15 and IL-18), cross-talk with other immune 
cells, and other micro-environmental factors [22].  
 NK cell receptors of the C-type lectin receptor family are among the most 
important in regulating NK cell function. Of this group - the activating NKG2D 
receptor binds as a homodimer mainly stress-induced (e.g. by DNA damage or 
virus infection) MHC class I chain related A and B proteins (MICA and MICB) and 
ligands from UL-16 binding proteins group (ULBP 1-4). This allows NK cells to 
distinguish and lyse malignant or virus-infected cells while sparing healthy tissue 
[23]. The anti-tumoral role of the NKG2D was confirmed in mouse models, where 
the receptor was shown to be involved in rejection of tumors carrying its cognate 
ligands Rae1β and H60 [24]. However, many tumor cells are able to produce TGF-
β and L-kynurenine or release soluble ligands, leading to decreased expression of 
NKG2D and inhibition of NK cell activity [25]. Three remaining receptors from the 
NKG group: NKG2A, NKG2C and NKG2E in contrast to NKG2D require 
heterodimerisation with KLRD1 (CD94) and recognize the non-classical MHC 
class I molecule - HLA-E in human and Qa-1b in mice. The former inhibits NK 
cells, whereas the latter two have activating function, since they associate with the 
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DAP12 adaptor protein [26]. Among them, worth mentioning is the potential 
antiviral role of the NKG2C receptor, which increases in expression on NK cells in 
response to CMV reactivation in patients after either hematopoietic cell or solid 
organ transplants. The expanded population persists after clearance of virus 
replication as a long-lasting and self-renewing subset with high functional 
competence [27].  
Another group of receptors present on the surface of NK cells is a family of 
natural cytotoxicity receptors (NCR) belonging to the Ig-superfamily. One 
representative of the group, the NKp44 receptor, needs stimulation of NK cells by 
IL-2 to be expressed and is known to bind proliferating cell nuclear antigen 
(PCNA) on rapidly proliferating cancer cells. Additionally, it was demonstrated that 
the HIV-1 envelope protein gp41 induces the expression of the recently identified 
mixed-lineage leukemia 5 (MLL5) protein, a ligand for NKp44 on the surface of 
non-infected CD4+ T-lymphocytes [28]. This process causes activation of NK cells 
and killing of autologous CD4+ T-lymphocytes, resulting in their depletion and an 
increase in viral load. The NKp44 receptor also binds viral hemagglutinins 
triggering NK cell cytotoxicity. The remaining family members (NKp30 and NKp46) 
are found on the surface of resting NK cells. The NKp30 receptor seems to have 
wide functionality. It was shown to bind HLA-B associated transcript 3 (BAT3), 
which is a stress factor appearing on the membrane of transformed cells or 
immature dendritic cells (iDC); and B7 homolog (B7-H6) expressed by K562 cells. 
In the case of CMV infection, the viral tegument protein pp65 binds NKp30 and 
allows viral escape by dissociating the CD3ζ-chain from the NKp30 complex 
thereby abolishing the activating signaling capacity of NKp30. Additionally, heparin 
sulfate proteoglycans present on tumor cells are common ligands to NKp30 and 
NKp46 [26, 28, 29]. The NCRs are responsible for eliminating many tumors and 
viral infections, since deletion of single NCR genes or functional blocking by 
antibodies significantly decreased NK cell activity in vivo and in vitro [30].  
In contrast to NCRs, the leukocyte inhibitory receptors (LIR) family fulfill 
mostly inhibitory functions by interacting with the low-polymorphic α3 domain of 
HLA class I molecules [31]. One of its members, LILRB2, was shown to associate 
with slower progression to AIDS in individuals carrying HLA-B*35, an HLA antigen 
preferentially presenting peptides with a tyrosine at position 8 to the LILRB2 
receptor. Similarly, the weak binding of some other HLA-B subtypes (B*57 and 
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B*27) to LILRB2 delays AIDS progression [32, 33]. The most important finding in 
the interaction with CMV was that another family member, LILRB1, binds the viral 
protein UL18, a structural viral homolog of the MHC class I molecule with a much 
higher affinity, protecting the virus from an immune response [34].  
NK cells possess the ability to recognize and bind Fc fragments of IgG1 
antibodies coating a target cell by virtue of the FcγIIIa receptor (CD16), what leads 
to target cell lysis by antibody dependent cellular cytotoxicity (ADCC) [35, 36]. 
Since they do not possess inhibitory FcγIIb receptor, like the others Fc receptor 
expressing cells, they seem to be main mediators of that mode of action. 
Activation by antibodies was demonstrated to overcome inhibitory signals resulting 
in cytotoxic effect and cytokine production [37]. 
 The DNAM-1 receptor (CD226) also belongs to the Ig-superfamily. It acts 
as a co-stimulatory and activating receptor, is expressed constitutively on 
approximately 50% of NK cells and binds Polio virus receptor (PVR or CD155) and 
Nectin-2 (CD112), which are expressed on some tumor cells (e.g. colorectal 
carcinoma) [38, 39]. The receptor has an additional role in co-stimulation of T-
lymphocytes, and in cooperation with the lymphocyte function-associated antigen-
1 binds intercellular adhesion molecules (ICAMs) fulfilling an important function in 
NK cell migration [40].  
  These receptors comprise the most important but do not represent all 
receptors present on the surface of NK cells. The variety of receptors, their 
different repertoires and expression levels shows, from one side, the wide ability of 
NK cells to detect either malignant or virus-infected cells and hence their 
importance as an arm of innate immune system, but also the complexity of 
modulation of their activity from another side. However, for the purpose of this 
thesis the remaining part of the introduction focuses on characteristics of the KIR 
family, its role in the function of NK cells and its potential clinical significance.  
 
KIR gene structure and regulation of expression 
 
KIR genes family and its subgroups 
 
The human KIR gene family occupies a 100-200 kbp stretch on chromosome 19 
(19q13.4) within the leukocyte receptor complex and consists of fifteen KIR gene 
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loci (2DL1, 2DL2/L3, 2DL4, 2DL5A, 2DL5B, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 
3DL1/S1, 3DL2, 3DL3, 2DP1 and 3DP1). The last two members are pseudogenes.  
These genes are 14 – 16 kbp long and most possess nine exons, which separate 
fragments responsible for expression of different functional regions of KIR proteins 
[19, 41]. Aligned KIR genes differ only in single nucleotides and therefore exhibit 
high sequence similarity. They most probably evolved through duplications, 
mutations, deletions, recombination and unequal crossing-over form an ancestral, 
prototypical gene 3DL0, which is highly conserved in primates [42]. The KIR genes 
are divided into three groups [43]:  
I) Type I KIR2D encode extracellular protein immunoglobulin-like domains D1 
and D2 and include the following members: KIR2DP1, KIR2DL1-3 and 
KIR2DS1-5. All are composed of eight exons and one pseudoexon 3 
sequence, which is inactive. KIR2DL1 and KIR2DL2 possess a common 
deletion in exon 7. KIR2DL1-3 also differ from KIR2DS1-5 in the length of 
exon 9 encoding the cytoplasmic tail. 
II) Type II KIR2D include KIR2DL4 and KIR2DL5 containing fragments 
encoding D0 and D2 domains and are characterized by the presence of a 
translated exon 3, and deletion of the region corresponding to exon 4 in 
Type I KIR genes. Additionally, KIR2DL4 differs from all the other genes by 
having a longer exon 1.  
III) KIR3D genes are comprised of 4 members: KIR3DL1-3 and KIR3DS1 
possessing D0, D1 and D2 domains, and the non-coding pseudogene 
KIR3DP1. All of them vary in terms of length of exon 9 encoding the 
cytoplasmic tail. KIR3DS1 possesses a shorter exon 8 sequence than the 
others, whereas KIR3DL3 lacks exon 6. The pseudogene KIR3DP1 lacks 
exons 6-9 and in some alleles also exon 2. 
The biggest difference in the length of KIR genes is notable in the fragment 
encoding the intracellular tail varying from 14 to 108 amino acids [18, 44, 45]. 
Their domain organization is schematically illustrated in Figure 1. 
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Figure 1. KIR loci structure (modified from [44]). 
 
KIR haplotypes 
 
KIR genes in humans are organized into at least 40 distinct haplotypes, which 
have been entirely sequenced [46]. Each haplotype possesses four framework 
genes: KIR3DL3 is located at the centromeric end, KIR3DP1 and KIR2DL4 are 
present in the middle and KIR3DL2 flanks the telomeric end. Between those 
constant framework genes there is a varying content of inhibitory and activating 
KIR genes; all of them arranged at distances of about 2.4 kbp from each other [41, 
45, 47]. This variability is the basis for the classification of KIR haplotypes to A and 
B groups. The former is less variable and contains mainly inhibitory KIR genes 
(2DL1, 2DL3, 3DL1, 2DS4 and 2DP1), whereas the latter additionally involves 
activating KIR genes, which vary in number and combinations. Additionally, in 
these configurations KIR2DL2 and KIR2DL5 may be present. KIR2DL2/L3 and 
KIR3DL1/S1 occupy the same locus and constitute a kind of framework genes, 
because in each individual at least one from them is found. The total KIR receptor 
repertoire is the result of the combination of products expressed by KIR genes 
located in both centromeric and telomeric parts of the haplotype [44, 48]. 
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KIR expression regulation 
 
The expression of KIR genes is heterogeneously regulated. Gene regulation 
involves a complex layer of epigenetic modifications such as methylation or 
deacetylation [49, 50]. Further analysis of intergenic regions of KIR revealed and 
characterized more precisely promoters, which regulate and coordinate the KIR 
gene transcription: 
- Distal promoters, devoid of cytosine-phospho-guanine and therefore 
independent on DNA methylation, possess binding sites for the transcription 
factor c-Myc located 1150 bases upstream from their translational sites for 
KIR2DL1/2DS1/2DS3/2DS5 and KIR3DL1/3DL2/3DS1 and 1190 bases 
upstream from the location for KIR2DL2/DS2/2DL3/3DL2. An important 
player inducing the c-Myc transcription factor is IL-15, which then drives 
distal transcription [51]. During NK cell development this process starts at 
CD56bright stage and persists in CD56dim NK cells. The acquisition of IL-15 
responsiveness is therefore a key feature required for their final function 
[52]. The transcription from the distal promoter triggers activation of 
proximal promoter [51]. 
- Proximal promoters are about 270 bases long and include many 
overlapping transcriptional binding sites [53]. The function of these 
promoters is dependent on DNA methylation, which correlates inversely 
with transcription level of a particular allele. They exhibit a bidirectional 
activity, i.e. both sense (forward) and antisense (reverse) transcription is 
possible. The higher frequency of the former is proportional to the increase 
in gene expression. The antisense activity correlates negatively with 
amount of transcripts. The distal and the antisense proximal transcripts 
fragments overlap. That leads to production of double-stranded RNA 
(dsRNA), which is then processed to a small 28-base RNA product, found 
in NK cells to be mediator of maintenance the methylated state of the 
proximal promoter. As confirmation, the presence of that dsRNA transcript 
is correlated to silencing of KIR gene expression [51, 54].  
- KIR intron 2 promoters whose antisense transcript is found in development 
stages of NK cells and is responsible for maintenance of DNA methylation 
K. Czaja                                                      INTRODUCTION 
14  
 
 
 
 
 
within the proximal promoter. It was shown to be bound by the transcription 
factor - myeloid zinc finger 1, which is responsible for the start of 
transcription [51].   
Summarizing the regulation of KIR genes expression at the epigenetic level, 
it appears that during NK cell development the intron 2 promoter produces an 
antisense transcript. It blocks KIR expression by establishing the methylation of 
proximal KIR promoters [55]. During further development, the myeloid zinc finger 1 
is downregulated, and in consequence transcription from the intron 2 promoter 
decreases. Upon reaching the CD56bright stage, NK cells become responsive to IL-
15 and as a consequence the c-Myc transcription factor is bound to the distal 
promoter. That, in turn, starts chromatin modifications and initiates demethylation 
of proximal promoters, so that the KIR expression goes along with the 
transformation from CD56bright to CD56dim NK cells. At that stage the bidirectional 
transcription decides, whether sense transcript allows expression, or the antisense 
transcripts causes de novo methylation of proximal promoter, blocking expression 
(Figure 2) [51].  
Besides the epigenetic regulation process, there exist other internal factors 
influencing the expression and transport of KIR proteins to the cellular surface. 
The high polymorphism of KIR exons was shown to influence their expression 
levels on the cell surface. Based on the binding of the DX9 antibody recognizing 
KIR3DL1, it was noted that there are three surface expression variants: high (*001, 
*002, *008, *009, *015, and *020), low (*005, *006, and *007), or null (*004). The 
reason for the lack of expression the *004 allele lies in amino acid substitution at 
positions 86 and 182 [56]. Surprisingly, absence of cell surface expression does 
not imply loss of functionality, as for *004 a delaying effect regarding progression 
to AIDS was demonstrated [57]. In analogy, KIR2DS4*003 is not expressed on the 
cell surface, representing a so-called “deleted” phenotype. This subtype is the 
most prevalent allele, making some individuals of haplotype A totally devoid of 
activating KIRs [58]. Similar studies concerning the influence of gene 
polymorphisms on the surface expression were done for KIR2DS3. This protein is 
always expressed intracellularly. Mutation at crucial locations causes it 
externalization in vitro [59].  
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Figure 2. Regulation of KIR gene expression. Black bars indicate promoter regions and numbered 
rectangles indicate exons (from [60]). 
 
Another internal factor playing a role in trafficking and surface stability of 
activating KIRs is the adapter protein DAP12. The interaction between immature 
activating KIR proteins and DAP12 starts in the endoplasmatic reticulum (ER), 
what not only improves the transport efficiency towards cellular membrane, but 
also a proper glycosylation pattern. The interaction with the adapter protein 
promotes correct folding of the KIR and protects its binding by factors causing 
internalization of the receptor [61].  
 
KIR repertoire formation 
 
First observations concerning Ly49 and KIR repertoire in mice and humans 
suggested that the probability to find an NK cell clone expressing two or more 
receptors is equal to the mathematical product the total frequency of cells carrying 
these receptors (“product rule”: Pall KIR = PKIR1 x PKIR2 x PKIR3 where P is equal to 
probability of expressing a particular KIR receptor) [62-64]. A verification of that 
theory and conclusions about KIR repertoire formation came initially from studies 
on mouse Ly49 receptors. MHC molecules were shown to influence the Ly49 
repertoire. β2-microblobulin deficient (hence MHC negative) mice exhibited a 
higher frequency of Ly49 positive NK cells in comparison to wild-type mice. 
Conversely, there was less frequent co-expression of two Ly49 receptors in mice 
carrying their cognate ligands [65, 66]. Parham et al. confirmed the dependence of 
KIR repertoire on HLA configuration indicating a bias towards the optimal missing-
self response [67]. A segregation of KIRs to self- and non-self in other studies 
demonstrates a ligand-instructed model of KIR acquisition. It was shown that in 
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haplotype A, the frequency of KIR2DL1 increases in homozygous individuals 
bearing its ligand HLA-C2, and similarly a higher frequency of KIR2DL3 is 
observed in HLA-C1 homozygous individuals. That difference disappears, if an 
individual possesses KIR2DL2, which is explained by partial overlap of specificity 
and function of KIR2DL2 and KIR2DL1/2DL3 [68]. The recent complex studies 
support dependence of KIR repertoire not only on their cognate ligands but also on 
other KIRs. It was stated that the presence of KIR2DL2, but also KIR2DS1 and 
KIR2DS2 restrict KIR2DL1 bearing NK cell subpopulation [69]. Noteworthy, the 
KIR repertoire is also dependent on the presence of receptors from other families. 
NKG2A expression was inversely correlated with expression of inhibitory KIRs 
[67]. Summarizing, the acquisition of the KIR repertoire is not explainable 
exclusively by a “product rule” and is complex process, which requires further 
investigation. A great help here could be knowledge of ligands for all the inhibitory 
and activating receptors. That would give a possibility to better predict behavior of 
NK cells in physiologic and pathologic states. !
KIR nomenclature, structure and signaling 
 
KIRs consist of 306 to 456 amino acids, depending on the number of extracellular 
domains and the length of the intracellular tail. The extracellular domain of a KIR 
comprises either 2 or 3 IgG-fold (like) domains, as indicated by the first digit in the 
respective receptor index name. As previously discussed, there exist three types 
of receptors having the domains D0 (96 aa), D1 (102 aa) and D2 (98 aa) in 
different configurations: KIR2DL1-3 and KIR2DS1-5 (D1+D2) due to lack of exon 3 
encoding the D0 domain; KIR2DL4-5 (D0+D2) devoid of exon 4 encoding the D1 
domain; and all KIR3D (D0+D1+D2). All KIRs share thus the D2 domain. The 
domains form angles between each other. Each newly biosynthesized KIR protein 
possesses a leader peptide, which is 21 aa long (23 aa long in case of KIR2DL4). 
This is then cut off during transport of the protein to the cellular membrane. The 
domains are located on a short stem (24 aa long with the exception of KIR3DL3 
having only 7 aa) forming together the extracellular part, connected to a 
transmembrane part (usually 20 aa, but 19 aa for KIR2DL1 and KIR2DL2) [43, 44, 
70]. The structure of this part forms the ligand recognition specificity. Since KIRs 
evolved in parallel with HLA molecules, they are also highly polymorphic, 
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especially in their extracellular part, and it was necessary to introduce a 7-digit 
nomenclature system similar to that used in HLA (Figure 3) [71].   
KIR2DL1*0020201*
Acronym*
Two*Ig5like*domains*
Long*cytoplasmic*tail*
First*2DL*protein*described*
Separator*
Member*of*the*second*series*of*KIR2DL1*proteins*
Synonymous*DNA*subsGtuGon*within*the*coding*region*of**KIR2DL1*002**
Synonymous*DNA*subsGtuGon*within*the*non5coding*region*of*
KIR2DL1*00202**
 
Figure 3. KIR nomenclature system (modified from [71]). 
 
The intracellular tail of KIRs may be short (marked by an S) or long (marked 
by an L). The structure of this part specifies whether a KIR is activating or 
inhibiting. The short-tail KIRs recruit the DAP12 adaptor protein already in the ER, 
prior to transport to the cell membrane. DAP12 carries an immunoreceptor 
tyrosine-based activation motif (ITAM). The KIR-DAP12 complex, upon binding of 
a ligand, induces activation of protein tyrosine kinases (e.g. Syk, ZAP-70) and a 
further downstream phosphorylation of adaptor proteins, like LAT, SLP-76 or Shc. 
This results in cytoskeleton remodeling and mobilization of lytic granules 
containing perforin and granzymes. The long cytoplasmic tail contains two 
immunoreceptor tyrosine-based inhibitory motifs (ITIM) and upon ligand binding 
becomes phosphorylated, resulting in recruitment of SHP-1 or SHP-2 
phosphatases. Both phosphatases target phosphorylated Syk-family protein 
tyrosine kinases, src-family protein tyrosine kinases and adaptor proteins 
interrupting the activating signal [72]. Therefore, the function of NK cells is 
regulated by the balance between activation and inhibition (Figure 4).  
The KIR2DL4 constitutes an exception to this rule. This is due to presence 
of only one ITIM and a charged arginine residue in transmembrane part, which 
associates with FcεR-Iγ [73]. Engagement of that receptor, which is mostly located 
in endosomes, causes activation of NK cells resulting in cytokine secretion. Its 
ligand is a soluble form of HLA-G coming from trophoblast. The KIR2DL4 in 
therefore involved in remodeling of maternal vasculature in early period of 
pregnancy [74]. 
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Figure 4. Coupling of inhibitory and activating signaling in NK cells (modified from [75]). 
 
KIR ligands and function !
Protection from killing by NK cells was found to be conferred by HLA class I 
molecules [76]. Antibody blocking of KIRs abolished the inhibitory effect and 
restored lysis of P815 cells transfected with HLA [14]. The interaction between KIR 
and HLA is based on hydrogen bonds and charge complementarity. In general, 
KIR2DL1 recognizes HLA-C (group 2) and KIR2DL2/3 detects HLA-C (group 1). 
Differential binding is based on a polymorphism at position 80 of the α1-domain in 
the HLA molecule, with specificities based on asparagine (group 1) or lysine 
(group 2) [77]. KIR2DL2/L3 shares some binding specificity with KIR2DL1, 
recognizing HLA-C*0501 and -*0202 and additionally HLA-B*4301 and -*7301. 
The binding region also covers the C-terminal end (positions 7 and 8) of peptides 
presented in the HLA context. By crystal structure, it was shown that there are 16 
residues in KIR2DL receptors participating in the contact with α1- and α2-domains 
of HLA-C molecules. Differences in these residues result in changes in specificity 
and strength of binding to particular ligands. The activating counterparts KIR2DS1 
and KIR2DS2 bind group 2 and group 1 ligands from HLA-C respectively, but with 
lower affinity [69, 70]. However, the peptide presented in complex also influences 
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the binding, and it was shown that EBV infection shifts the affinity from inhibitory 
receptor KIR2DL1 towards its activating counterpart [78]. 
The crystal structure of KIR3D receptors was not elucidated yet, but it was 
demonstrated that the D1 and D2 domains are responsible for binding and that the 
D0 domain, which is the most polymorphic, may enhance contact with a ligand or 
also contribute to binding [79, 80]. The D0 domain influences surface expression. 
The substitution of valine by leucine in position 18 enhances expression, whereas 
substitution of leucine by serine in position 86 abolishes the surface expression 
(e.g.: 3DL1*004 or 3DL1*053) [56]. The KIR3D specificity is directed towards HLA-
B allotypes possessing the Bw4 epitope, which is encoded by amino acids in 
locations 80-83  (IALR, TALR, TLLR) in the α2-domain [70, 81]. The remaining 
HLA-B allotypes, like most HLA-A antigens, contain the Bw6 epitope, and do not 
bind to KIR3DL1. The exceptions are the following HLA-A antigens: A*23, A*24 
and A*32 having also the Bw4 motif (IALR) in the mentioned location [82]. Within 
the Bw4 epitope, KIR3DL1 differentially binds Thr80 and Ile80, with the latter 
displaying a stronger interaction [83]. Additionally, the interaction between 
KIR3DL1 and HLA-Bw4 can be modified by the repertoire of peptides presented, 
as shown by the example of HLA-B*2507 [41, 84]. Despite a high structural 
similarity, no interaction between common KIR3DS1 alleles and HLA-Bw4 could 
be detected.  
Further search of candidates for HLA class I ligands to KIRs led to 
discovery of an interaction between KIR3DL2 and HLA-A*03 and A*11 [85]. The 
KIR2DL4 receptor was shown to bind HLA-G molecules and play a role in 
maternal tolerance to trophoblast cells devoid of HLA-A and HLA-B molecules 
[86]. The ligands to KIR2DL5 and KIR3DL3 remain unknown. KIR2DS4 
demonstrates the highest structural similarity to KIR2DL2, but does not share 
binding specificity. Using conjugates of the extracellular domains of KIRs with 
immunoglobulin Fc parts (KIR-Fc) it was demonstrated that KIR2DS4 reacts with 
HLA-A*1102, HLA-C*1602, -*0202, and -*0501 [87]. However, the functional 
consequences of this interaction were not confirmed yet in vitro. The ligands for 
KIR2DS3 and KIR2DS5 are at present unknown. All KIRs and their known ligands 
are summarized in Table 1. 
As described before, the principal function of inhibitory KIRs seems to have 
been identified in protection from NK cell killing. Downregulation of the expression 
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of their ligands causes a malignant or virus-infected cell to become susceptible to 
NK cell attack. For the activating KIRs the function is more elusive. Only for 
KIR2DS1 more efficient killing of dendritic cells and T-cell blasts as functional 
confirmation of binding to HLA-C2 molecules was demonstrated [88]. The 
KIR2DS4 was shown to enhance killing of melanoma cell lines, but since the cell 
lines used did not express any HLA class I molecules, it is supposed that 
activating KIRs might recognize ligands outside the HLA context. 
 
Receptor No. of alleles Ligand 
KIR2DL1 43 HLA-C2: C*02, C*04, C*05, C*06 
KIR2DL2 28 HLA-C1: C*01, C*03, C*07, C*08  
Some HLA-C2: C*0501, C*0202, C*0401  
Some HLA-B: B*4601, B*7301 
KIR2DL3 34 HLA-C1: C*01, C*03, C*07, C*08  
Some HLA-C2: C*0501, C*0202  
Some HLA-B: B*4601, B*7301 
KIR2DL4 46 HLA-G 
KIR2DL5A/B 41 unknown 
KIR3DL1 73 HLA-B expressing Bw4 epitope  
Some HLA-A: A*23, A*24, A*32 
KIR3DL2 84 Some HLA-A: A*03, A*11 
KIR3DL3 107 unknown 
KIR2DS1 15 HLA-C2: C*02, C*04, C*05, C*06 
KIR2DS2 22 HLA-C1? 
KIR2DS3 14 unknown 
KIR2DS4 30 HLA-C: C*0501, C*1601, C*0202 
KIR2DS5 16 unknown 
KIR3DS1 16 unknown 
Table 1. KIRs and their known ligands; number of alleles is given for April 2011 (modified from 
[89]). 
  
NK cells may respond in several ways to activating signals. The release of 
lytic granules containing perforin and granzymes causes disruption of the cell 
membrane in target cells. This promotes apoptosis in target cells leading to their 
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death [22]. Moreover, NK cells produce chemokines and cytokines after target cell 
recognition, orchestrating the innate and adaptive immune response [90]. This 
immunoregulatory function is mainly attributed to the CD56bright subset of NK cells, 
whereas CD56dim NK cells exhibit predominantly cytotoxic function. IFNγ released 
by activated NK cells inhibits the viral replication and has immunostimuatory 
effects. TNF-α induces apoptosis by cell-death receptors on target cells [22, 91]. 
NK cells are also able to stimulate monocytes to extravasation, and induce 
progenitor cell development towards granulocytes by secretion of 
granulocyte/macrophage colony stimulating factor (GM-CSF) [92]. 
Interactions (or lack of them) between KIRs and their ligands determine in 
high extent the antiviral and antileukemic function of NK cells. There are clinical 
data indicating indirectly their role. In some cases these correlations, observed in 
humans are confirmed in mouse models.  
 
KIR-mediated NK cell function in viral infections 
 
Natural killer cells are able to recognize a variety of viruses with the broad 
spectrum of receptors they carry. The complex role of the most important 
receptors was characterized above. The focus of this part lies in the antiviral role 
of KIRs. 
A role for inhibitory KIR in viral infections was demonstrated in the case of 
HIV infection, where the presence of KIR3DL1 with its ligand HLA-Bw4 was shown 
to be protective regarding progression to AIDS [93]. That is supposedly due to 
downregulation of HLA class I molecules by the virus, which triggers a strong 
“missing-self” effect [94]. However, some viruses avoid that response by 
expression of surrogate HLA proteins as it was shown e.g. for the mCMV m157 
protein, which binds to inhibitory Ly49 receptors [95]. On the other hand, weak 
interactions between inhibitory KIRs and their ligands are easier to overcome by 
activating signals during viral infection. This was shown to be relevant in hepatitis 
C infections. Of the two receptor-ligand pairs: KIR2DL2-HLA-C1 and KIR2DL3-
HLA-C1, the latter has a lower affinity leading to decreased inhibition, and 
resulting in better resolution of infection [96]. This is similar to the role of the 
LILRB2 receptor, whose weaker affinity to some HLA class I molecules causes 
delayed HIV progression. This decreases the NK cell activation threshold, which 
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may be additionally induced by unknown activating ligands upon infection or by 
change of the peptide repertoire in the HLA context, shifting NK cell signaling from 
inhibition towards activation. An argument supporting the latter theory could be 
KIR2DS1 binding to HLA-C2 ligands in complex with peptides of EBV origin on 
target cells [97]. Besides, some viral infections influence the expression of NK cell 
receptors. Murine CMV shapes the mouse Ly49 repertoire. That might suggest the 
antiviral role of KIRs, which are their analogues [98, 99]. The influence of human 
CMV on KIRs repertoire is subject of this thesis. 
Little is known about an antiviral role of activating KIRs. Genetic analysis of 
HIV-positive patients has shown that the presence of KIR3DS1, in combination 
with HLA-B Bw480Ile, delays the progression to AIDS. This association and also 
the high structural similarity to the inhibitory counterpart suggest a receptor-ligand 
relation between these two molecules [100]. There are limited data suggesting that 
aKIRs contribute significantly to the control of CMV infection. Studies in HSCT 
recipients clearly show the effect that the aKIR genotype has on decreased CMV 
reactivation incidence and, consequently, improved survival rates [101, 102]. 
Other studies have shown that the most protective effect against the virus 
reactivation in HSCT patients is achieved if donors carry either KIR2DS2 and 
KIR2DS4, or more than five aKIR genes [103]. This correlation supports a possible 
role of activating KIR in anti-CMV immunity. Our own analysis, performed in 
patients after kidney transplants, has shown a significant decrease in CMV 
reactivation in patients carrying more than one aKIR (individuals with at least one 
B haplotype) compared to individual homozygous for the haplotype A [104]. 
Remarkably, the protective effect is limited to CMV infection and not seen for EBV, 
HSV, or BKV. An additional analysis enabled us to map the locus of resistance to 
the telomeric part of the B haplotype KIR gene complex, which may contain three 
aKIRs: -2DS1, 2DS5, and 3DS1 [105]. Unlike the studies on HSCT patients, we 
were unable to confirm the role of KIR2DS2. 
These data suggest the variegated antiviral role of KIRs on NK cells. The 
deeper explanation of mechanisms and interaction between them and the infected 
cells could be useful to predict the individual immune response. As earlier 
mentioned, that is not only beneficial function of KIRs.  
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KIR-mediated NK cell function against leukemias  
 
As discussed, the antitumoral role of NK cells was discovered more than 30 years 
ago. A correlation between increased risk of cancer with low cytotoxicity of 
peripheral NK cells has been shown in several studies [106-108]. Conversely, 
infiltration of tumors by NK cells is beneficial, especially if supported by cytokine-
mediated activation [109].  
The inhibitory KIRs participate in elimination of tumor and leukemic cells in 
accordance to ‘missing-self’ hypothesis, if they are not able to detect their cognate 
HLA ligand. The lack of inhibition causes triggering of their cytotoxicity. This 
feature is used in hematopoietic stem cell transplantation, where a mismatch 
between KIRs and ligands increases therapeutic efficacy [110]. Additional studies 
showed an impact of KIRs on the risk to develop malignant diseases. For 
example, in a pediatric cohort, carrying KIR2DS2 was shown to be associated with 
decreased risk of B-ALL. In general the higher number of activating KIRs had a 
statistically significant protective influence against ALL in children [111]. Another 
role for KIR was found regarding reduced relapse risk of AML after HLA-matched 
sibling transplants, if the donor for hematopoietic stem cell transplantation (HSCT) 
carried all three KIR2DL5A, KIR2DS1 and KIR3DS1 together [112]. A beneficial 
effect regarding leukemia relapse and mortality was confirmed in other studies of 
patients transplanted for AML, with a protective role of the telomeric part of the 
haplotype B [113]. In contrast, a similar analysis of AML patients receiving T-
replete transplantation showed a benefit if at least one haplotype B of KIRs in 
unrelated donor was present [114]. Further investigation of the impact of activating 
KIRs more precisely pointed out the protective role of the centromeric part of the 
haplotype B [115]. Unfortunately, due to high linkage disequilibrium between KIR 
genes, identification of a single protective locus is difficult. Besides, it would 
require functional confirmation, which was only shown for KIR2DS1. This receptor 
was demonstrated to be implicated in recognition of C1/C2 and C2/C2 T-cell 
blasts, patients’ leukemia blasts, and myelomonocytic DC [88, 116]. The 
antileukemic function of the remaining activating KIRs is a subject of that thesis.  
Similarly to viruses, malignant cells develop mechanisms to evade the 
activation of NK cells by missing-self mechanism or stimulating receptors. In the 
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example of melanoma the immunoediting process was shown. The initial contact 
of NK cells with cancer cells caused killing of the latter. However, long-term 
equilibrium between effector and target cells was established, and melanoma cells 
became NK cell resistant. This was due to increased HLA expression and also a 
consequence of IFNγ production by NK cells. On the other hand, IFNγ release was 
proportional to NK cell stimulation. Additional activation of the effector cells by IL-
15 partially overrode the effect [117]. In ALL, the resistance to NK cell lysis results 
from lack of activating signals [118].   
Importantly, the tumoral microenvironment may also influence NK cell 
function. For example, release of lactate from cells as a reduction product of 
cumulating pyruvate, and hypoxia cause impairment of NK cell function, mainly by 
decrease of perforin and granzyme production. Prostaglandin overproduction and 
secretion also produce a similar effect. Cancer cells possess an ability to release 
exosomes containing ligands for NKG2D, decreasing expression of that receptor 
by NK cells and their activity [119]. Additionally, by production of cytokines (e.g. 
TNFα, stromal-cell derived factor-1 - SDF-1 and CCL2) they attract myeloid-
derived suppressor cells (MDSC) producing IL-10, which is anti-inflammatory 
cytokine and decreases production by macrophages of NK activity-triggering IL-12 
[119].  
These facts collectively confirm an antileukemic and antitumoral role of NK 
cells, and encourage further investigations to optimize their role in elimination of 
the malignant diseases.  
 
NK cells in clinical applications  
 
The capabilities of NK cells to distinguish “self” and “non-self” by KIRs encouraged 
clinical studies to manipulate receptor – ligand configurations in order to more 
efficiently combat malignant diseases. In AML or MM these differences in HLA 
ligands between donor and recipient resulted in lack of inhibition to subsets of 
transplanted NK cells missing their cognate ligands. Hence, these ‘alloreactive’ NK 
cells provide advantages in HSCT. Their application allows elimination of leukemic 
blasts, and protects from rejection and graft versus host disease [110]. The 
preliminary success of that therapy encouraged clinicians to inject mature KIR-
mismatched NK cells to children suffering from AML, which resulted in successful 
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engraftment and good tolerance [120]. Furthermore, in MM patients the transfer of 
purified and IL-2 stimulated NK cells before autologous HSCT didn’t result in graft 
rejection. The activated NK cells survived in vivo and displayed increased killing 
capacity of leukemic blasts in vitro [121]. NK cell transfer was also successfully 
applied after mild conditioning preventing rejection without HSCT in case of AML 
and other malignancies [89, 122]. The systemic toxicity of IL-2, and its role in 
expanding regulatory T-cells encouraged clinicians to search for an alternative. 
Preliminary data suggest that it might be substituted by IL-15, IL-12 or IL-18 to 
enhance NK cell activity [123]. The adoptive transfer of pre-activated NK cells is 
also applied in order to support HCST of CD34+ hematopoietic stem cells, since 
the development of functional KIR-expressing NK cells takes 6-8 weeks. That time 
period exposes a patient to a risk of relapse without alloreactive NK cell infusion 
[124].  
Another way to provoke a ‘missing-self’ reaction is to apply a monoclonal 
antibody blocking inhibitory KIRs. Such an antibody (IPH2101) binds 
KIR2DL1/DL2/DL3 receptors expressed on about 50% of NK cells and is in clinical 
development. Its biggest advantage lies in the possibility to apply it universally, i.e. 
independently on KIR and HLA configuration. The phase I trials in MM patients 
confirmed its safety at full inhibitory KIR saturating concentration [125]. The 
literature data shows even better efficacy of the IPH2101 antibody if applied with 
chemotherapy, bortezomib or lenalidomide, due to additive therapeutic effects 
against MM [126]. The antileukemic application of homologous anti-Ly49 
antibodies was confirmed in mice. An additional advantage of that therapy was 
persistence of the receptor inhibition for several weeks without interference in NK 
cells reactivity [127]. 
Monoclonal antibodies directed against antigens expressed by particular 
tumors induce ADCC in NK cells. One of them is rituximab, recognizing CD20 
molecule on the surface of B-cells and therefore applied in therapy against CLL 
and non-Hodgkin lymphomas. Nowadays, another improved antibody recognizing 
the same antigen with higher affinity, named GA101 is in preclinical phase [128]. 
Studies of our group show that the antibody is able to override KIR inhibitory signal 
counterbalancing ADCC, especially if more than one cognate HLA ligands for KIRs 
are present in an individual. Similar findings emerged from studies with bispecific 
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antibodies CD16x33, which in AML were also able to overcome the KIR inhibitory 
signaling [129].  
Taken together, NK cells constitute a highly valuable therapeutic tool and 
further optimization of their more efficient activation or abolishing their inhibitory 
signals is a proper way for improving outcome of leukemia patients. A more 
precise role of activating KIRs, from which only the function of KIR2DS1 positive 
NK cell clones was confirmed in clinical settings and in vitro [88, 113], in the 
elimination of leukemic cells remains still to be evaluated.  !
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!
AIMS OF THE THESIS 
 
Referring to literature data indicating antiviral and antileukemic activity of human 
NK cells mediated by activating killer cell immunoglobulin-like receptors, the 
general aim of this thesis is to dissect more precisely their biological function and 
evaluate their diagnostic and immunotherapeutic potential.  
In the first project (Project 1), we search for factors predicting maintenance 
of a low viral load in HIV patients undergoing structured treatment interruption. 
Here, certain genes responsible for expression of KIRs and their ligands, and also 
single nucleotide polymorphisms linked to a qualitative or quantitative repertoire of 
expressed HLA molecules, which were shown to delay HIV progress in untreated 
patients, are taken into consideration.  
Further studies (Project 2) take a closer look on the antiviral function of 
KIRs. We perform an assessment of their frequency in CMV-infected healthy 
donors and compare it to uninfected individuals. Additionally, we analyze changes 
in KIR receptor repertoire of both subgroups after challenging them with CMV-
infected fibroblasts in functional assays and assess underlying molecular 
mechanism. 
A broader understanding of the function of KIRs requires development of 
adequate research tools (Project 3). We produce soluble forms of KIRs and create 
NK cell lines expressing each of them separately. Moreover, we revise anti-KIR 
antibodies specificity and introduce a new flow cytometric sample-analysis 
strategy. 
We use soluble forms of KIRs in studies concerning antileukemic 
significance of individual KIRs (Project 4). We perform binding screening of KIR-Fc 
to a panel of leukemic cell lines of different origin. We test binding affinity and 
check the blocking of binding by antibodies in order to identify potential ligands. 
We also try to use KIR-transduced cell lines to confirm their binding 
consequences. We apply the new flow cytometric sample staining strategy to 
assess functional consequences of activating receptor binding.  
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Abstract 
 
After structured treatment interruption (STI) of treatment for HIV-1, a fraction of 
patients maintain suppressed viral loads. Prospective identification of such 
patients might improve HIV-1 treatment, if selected patients are offered STI. 
 
We analyzed previously identified genetic modulators of HIV-1 disease 
progression on patients’ ability to suppress viral replication after STI. 
Polymorphisms in the genes KIR3DL1/KIR3DS1, HLA-B, HCP5, and a 
polymorphism affecting HLA-C surface expression were analyzed in 130 Swiss 
HIV Cohort Study patients undergoing STI. Genotypes were correlated with viral 
load levels after STI. 
 
We observed a statistically significant reduction in viral load after STI in carriers of 
HLA-B alleles containing either the Bw480Thr or the Bw480Ile epitope (mean 
adjusted effect on post-STI viral load: -0.82 log, p<0.001; and -1.12 log, p<0.001, 
respectively). No significant effects were detected for the other polymorphisms 
analyzed. The likelihood of being able to control HIV-1 replication using a pre-
specified cutoff (viral load increase <1000 copies/ml) increased from 39% in Bw4-
negative patients to 53% in patients carrying Bw4-80Thr, and to 65% in patients 
carrying Bw4-80Ile (p=0.02). 
 
These data establish a significant impact of HLA-Bw4 on the control of viral 
replication after STI. !!!!!!!
K. Czaja                                                             PROJECT 1. 
31  
 
 
 
 
 
!
Introduction 
 
Antiretroviral therapy (ART) enables long-term control of HIV-1 infection through 
suppression of viral replication in the majority of treated individuals. This leads to 
substantial immune reconstitution, significantly delays morbidity and mortality, and 
transforms HIV infection into a chronic disease [1]. However, ART is not curative 
and life-long pharmacological treatment is required, which can lead to numerous 
adverse effects. Depending on the drug combination applied, cardiovascular 
events, hepatotoxicity, neuropathy, renal dysfunction and lipodystrophy may occur 
[2]. Additional concerns regarding continuous ART are the induction of drug 
resistance, high costs, and treatment fatigue in patients. Structured treatment 
interruption (STI) strategies have therefore been explored in patients with viral 
replication suppressed under ART [3–6]. Overall, results were disappointing, with 
a significant proportion of patients showing rapid increases in viral load, declining 
CD4 T-cell counts, and an increased risk for disease progression [4, 7]. However, 
a subgroup of patients is able to suppress HIV replication for prolonged periods of 
time after STI [8]. A marker identifying such patients would be of great practical 
value and might renew interest in STI. 
Several studies have identified genetic factors influencing the pretreatment 
set-point viral load and time to progression to AIDS in untreated patients: the first 
locus identified was human leucocyte antigen (HLA)-B [9]. The natural killer (NK) 
cell receptor pair killer cell immunoglobulin-like receptor 3DL1 
(KIR3DL1)/KIR3DS1 followed [10]. More recently, whole-genome association 
studies provided the information that two single nucleotide polymorphisms, found 
in or close to the HLA complex, both correlate with HIV viral load in untreated 
individuals [11]. The first (rs9264942) is located 35 kbp upstream of HLA-C (HLA-
C -35 C/T) and governs the level of surface expression of HLA-C [12]. The second 
(rs2395029) lies in the HLA complex P5 (HCP5) and is in strong linkage 
disequilibrium with HLA B*5701, the HLA-B allele associated with the strongest 
protection from disease progression. Interestingly, all of these polymorphisms are 
potentially associated with the function of NK cells, a subgroup of lymphocytes 
important in defense against viral infection: KIR3DL1 is an inhibitory receptor 
binding HLA-B antigens that carry the Bw4 epitope [13]. HLA-C is the ligand for 
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the NK cell receptors KIR2DL1, KIR2DL2, KIR2DL3 and KIR2DS1 [14]. KIR–HLA 
interactions are important during NK cell development, as only NK cells carrying 
inhibitory KIR and their HLA ligands acquire full functional competence [15]. As 
antiviral effects of NK cells have been shown to operate most effectively in states 
of low viral load [16], we hypothesized that these polymorphisms may have a role 
in predicting which patients are able to maintain suppressed viral load after STI. 
We therefore studied the association of these polymorphisms with the evolution of 
viral load after STI in 130 Swiss HIV Cohort Study patients. 
 
Patients and methods 
 
Study subjects 
 
Patients were recruited from Swiss HIV Cohort Study participants of the Strategies 
for Management of Anti-Retroviral Therapy (SMART), Swiss Spanish Treatment 
Interruption Trial (SSITT)/2nd SSITT, and STACCATO (A Trial of CD4 Guided 
Treatment Interruption, Compared to Continuous Treatment, for HIV Infection) 
trials [3–6]. Of note, patients enrolled in SSITT/2nd SSITT treated with granulocyte 
macrophage colony-stimulating factor were excluded from the present analysis. All 
patients gave written informed consent to their study treatment and to having their 
data analyzed. One-hundred and thirty patients with viral load data available at set 
point, and before and after treatment interruption lasting at least 7 days, were 
included in the study. Mean pretreatment set- point viral loads were calculated, if 
more than one value was available within 6 months before initiation of antiretroviral 
treatment. If patients underwent more than one STI, only the first interruption was 
considered in the analysis. Demographic data for the patient population are 
summarized in Table 1. 
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Patient age 
– Median (Range) 
 
  41 (22-71) 
Gender (n,%) 
–Male 
– Female 
 
 87 (67) 
 43 (33) 
Source of infection (n, %) 
– Blood products 
– Injection drug user 
– Heterosexual contact 
– Men who have sex with men 
– Other/unknown 
 
 1 (1) 
 13 (10) 
 57 (44) 
 55 (42) 
 4 (3) 
Ethnicity (n, %) 
– White 
– Black 
– Hispano-American 
– Asian 
 
 110 (85) 
 14 (11) 
 2 (2) 
 4 (3) 
Number of treatment interruptions 
– Median (range) 
 
 2 (1-5) 
Trial (n, %) 
– SITT* 
– 2nd SSITT* 
– SMART* 
– STACCATO * 
 
 76 (58) 
 18 (14) 
 13 (10) 
 25 (19) 
Table 1. Patient population.! *SSITT (5,6), Swiss Spanish Intermittent Therapy Trial; SMART (4), 
Strategies for Management of Anti-Retroviral Therapy; STACCATO (3), A Trial of CD4 Guided 
Treatment Interruption, Compared to Continuous Treatment, for HIV Infection.!
 
Genotyping 
 
The KIR genotype was assessed using sequence-specific primer (SSP) 
polymerase chain reaction (PCR) [17]. Alleles of KIR3DL1 differing in cell surface 
expression were discriminated by intermediate resolution allele-specific PCR into 
those carrying alleles with high (*h; 3DL1*001, *002, *003, *006, *008, *009, *015 
and *020), low (*l; 3DL1*005 and *007), or no surface expression (3DL1*004) 
using a combination of PCR SSP protocols previously described [18–20]. Patients 
were grouped into those expressing two high expression alleles (*h/*y) and those 
expressing at least one low-expressing allele (*l/*x) [21]. The KIR3DL1*004 allele, 
which is not expressed on the cell surface, was analyzed separately. 
KIR3DL1 ligands were typed using a real-time PCR method that 
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discriminates between the two types of HLA- Bw4, Bw4-80Thr and Bw4-80Ile [22]. 
The HLA-C35 single nucleotide polymorphism (SNP) (rs9264942) was typed using 
a pre-designed custom assay using TaqMan chemistry (Applied Biosystems, 
Foster City, CA). The SNP in HCP5 (rs2395029) was typed by direct sequencing 
(forward primer 5′-3′ ACG ATT CTC CTC ACA CTT ACA; backward primer 5′-3′ 
TCT CTC CCA AAA CCA CAC TC). 
 
Statistical analysis 
 
Viral load data were compared using nonparametric tests (the Mann–Whitney U-
test and the Kruskal–Wallis test). Values are reported as medians and interquartile 
ranges (IQRs). Correlations between variables were assessed by calculating 
Spearman’s rho. Generalized linear models were used to test the impact of the 
polymorphisms on the control of viral replication in multivariate fashion. All P-
values reported are two-sided. To account for multiple testing, we considered 
associations of P ≤ 0.01 as significant. 
 
Results 
 
HIV viral load at set point, on and off ART 
 
The distribution of pretreatment set-point viral loads, as well as viral loads before 
and after STI, is shown in Figure 1. The median pretreatment viral load was 4.73 
log HIV-1 RNA copies/ml (interquartile range 4.14–5.74 copies/ml). Immediately 
before treatment interruption, viral load was below the detection level in the 
majority (71%) of patients. Viral load increased after STI to a median of 3.06 log 
copies/ml (IQR 1.46–4.61 log copies/ml; Fig. 1a). 
The median interval between treatment interruption and viral load 
assessment off ART was 21 days (IQR 18–43 days). A significant correlation was 
found between this interval and the rise in HIV copy number (P=0.002; Fig. 1b). In 
addition – and as previously demonstrated [6, 23] – the pretreatment set-point viral 
load correlated significantly with the post-STI viral load (P < 0.001). The duration 
of STI and viral load at pretreatment set point were therefore included in 
multivariable analyses. 
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Figure 1. HIV viral load in patients at pre-treatment set point, before and after structured treatment 
interruption (STI). Horizontal lines represent medians, the box represents the interquartile range, 
and whiskers represent the 2.5 and 97.5 percentiles (panel A). A significant correlation was 
detected between the post-STI HIV viral load and the interval since interruption of ART (p=0.002, 
panel B), and between the set point viral load and the post-STI viral load (p<0.001, panel C). 
 
Impact of genetic polymorphisms on control of viral load 
 
Eighty-nine patients (68%) carried at least one HLA-B Bw4 allele. Bw4 alleles can 
be further separated into those carrying isoleucine or threonine at position 80 
(Bw4-80Ile and Bw4-80Thr, respectively). Functionally, alleles with isoleucine act 
as strong ligands, whereas alleles carrying a threonine act as weak ligands of 
KIR3DL1 [24]. The former were detected in 52 patients (40%) and the latter in 37 
patients (28%), whereas 41 patients carried no Bw4 alleles (32%). Patients not 
carrying a Bw4 allele showed a median post-STI viral load of 3.24 log copies/ml 
(IQR 2.21–4.29 log copies/ml), whereas the median post-STI viral load was 2.39 
log copies/ml (IQR 0–3.62 log copies/ml) in Bw4- positive patients (P = 0.003; Fig. 
2a). No difference was found between carriers of 80Thr and 80Ile subgroups of the 
Bw4 (median increase 2.40 and 2.39 log copies/ml, respectively; P = 0.66; Fig. 
2b). 
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We next analyzed the impact of allelic diversity within the KIR3DL1 locus in 
Bw4-positive patients. Of 125 KIR3DL1-positive patients, 84 tested positive for at 
least one Bw4 antigen. We found no difference between patients carrying 
KIR3DL1 alleles with high (*h/*x) and low (*l/*l) surface expression (median 
increase 2.91 and 2.71 log copies/ml, respectively; P = 0.57; Fig. 2c). Equally, the 
presence of the KIR3DL1*004 allele – which in conjunction with Bw4 has been 
shown to delay the progression to AIDS – had no significant impact on post-STI 
viral loads (median increase 2.65 vs. 2.91 log copies/ml, respectively; P = 0.58; 
Fig. 2d). 
The activating receptor KIR3DS1 – which segregates as an allele of 
KIR3DL1 – was contained in 45 patients’ genotypes (35%), of which 13 also 
carried Bw4Ile. The presence of KIR3DS1 with Bw4Ile has been shown to delay 
progression to AIDS [25]. In our setting, we found no difference in the rise in viral 
load between KIR3DS1+/ Bw4-80Ile+ patients (median increase 2.65 log 
copies/ml) and patients who did not carry either KIR3DS1 or Bw4- 80Ile or both 
(median increase 2.91 log copies/ml; P = 0.81; Fig. 2e). 
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Figure 2. Post-STI log HIV viral is significantly lower in patients carrying the HLA-Bw4 epitope 
(panel A). Within Bw4-positive patients, no significant differences are seen between patients 
carrying Bw4-80Thr or Bw4-80Ile (panel B), between patients carrying low-or high surface 
expression alleles of KIR3DL1 (panel C), or in patients which do or do not carry the KIR3DL1*004 
allele (panel D). The compound genotype KIR3DS1+/Bw4-80Ile+ does not significantly influence 
post-STI viral load (panel E), as so polymorphisms in HCP-5 and HLA-C min35 (panels F and G). 
 
Finally, we analyzed the impact of the SNPs in HCP5 and in HLA-C -35. 
Nine patients (7%) carried one G allele in the HCP5 locus, and all remaining 
patients were homozygous for the wild-type T-allele. The median viral load was 
lower in patients with HCP5-G (median 2.76 log copies/ml) compared with HCP5-
TT homozygous patients (median 2.85 log copies/ml). This difference was, 
however, not statistically significant (P = 0.90; Fig. 2f). At the HLA-C -35 locus, 79 
patients (61%) were homozygous for the major T-allele and seven patients (5%) 
were homozygous carriers of the protective C allele, whereas the remaining 44 
patients (34%) carried one copy of each allele. We found a lower post-STI viral 
load in homozygous carriers of the protective C allele (median 2.33 log copies/ml) 
compared with heterozygous patients (median 2.91 log copies/ml), and 
homozygous carriers of the T allele (median 2.81 log copies/ml). However, this 
difference did not reach statistical significance (P = 0.74; Fig. 2g). 
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Multivariable and categorical analysis 
 
To account for the possibility of an interaction between variables predicting HIV 
viral load evolution after STI, we used multivariable generalized linear models to 
analyze the impact of pretreatment viral load, the duration of STI and genotype. 
Results are summarized in Table 2. Importantly, the protective effects of both 
Bw4-80Thr and Bw4-80Ile were maintained in the analyses adjusted for other 
covariates including time of STI and pretreatment set-point viral load. 
 
Risk factor Change in log post   
STI viral load 
95% CI P 
HLA Bw4    
  No Bw4 (baseline) 
  Bw4-80Thr 
  Bw4-80Ile 
- 
- 0.82 
- 1.15 
- 
-1.27 to -0.36 
-1.61 to -0.70 
-  
<0.001 
<0.001 
HCP-5    
  Wild type (baseline) 
  Mutated 
- 
- 0.79 
- 
-1.52 to -0.06 
-  
0.04 
HLA-C -35    
TT (baseline) 
CT 
CC 
- 
- 0.02 
- 0.12 
- 
-0.37 to +0.42 
-0.91 to +0.66 
-  
0.90 
0.74 
Pretreatment viral load    
Increase per log +0.19 +0.02 to 0.35 0.03 
STI duration    
Increase per day +0.01 +0.002 to 0.014 0.006 
KIR3DL1 (Bw4+ only)    
  *h/*y versus *l/*x 
  *004 present versus absent 
+ 0.43 
 - 0.22 
-0.05 to +0.90 
-0.76 to -0.11 
0.08 
0.41 
KIR3DS1 (Bw4-80Ile+ only)    
  Present versus absent +0.00 -0.48 to +0.48 0.99 
Table 2. Multivariable analysis. CI, confidence interval; HLA, human leucocyte antigen; HCP-5, 
HLA complex P5; KIR, killer cell immunoglobulin-like receptor; STI, structured treatment 
interruption. 
 
Using a predefined cut-off of a post-STI viral load copy number of 1000 
copies/ml, the frequency of patients able to control viral replication increased from 
39% of Bw4- negative patients to 53% of Bw4-80Thr patients to 65% of Bw4-80Ile 
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patients (P = 0.02). None of the other polymorphisms analyzed showed any 
significant impact in this analysis. 
 
Discussion 
 
Previous studies have identified a number of genetic factors affecting viral load at 
diagnosis of HIV infection and the interval from seroconversion to the development 
of AIDS [10, 11, 26]. STI has been advocated as a therapeutic strategy in HIV-
infected patients. Although a minority of patients in STI trials were able to 
suppress viral replication off ART, this approach has largely been abandoned, 
after randomized studies had shown increases in complications following STI 
when compared with patients treated continuously [4]. A genetic profile identifying 
patients with a higher likelihood of being able to suppress viral replication might 
point towards pathways involved in the control of viral replication and may renew 
interest in STI. 
Our study found that an HLA-B allele containing the Bw4 public epitope 
conferred statistically significant protection regarding the rise in viral load after 
treatment interruption. No effect of KIR3DL1 alleles – which act as receptors for 
HLA-Bw4 – on post-STI viral load was detected. This may be a consequence of 
the relatively small sample size or be an indication that HLA-Bw4-related effects 
are the results of T-cell- rather than NK-cell-mediated immunity to HIV-1. Similarly, 
polymorphisms in HCP5 and in HLA-C -35 did not significantly influence post-STI 
viral loads in this analysis. However, the number of patients carrying the 
respective protective alleles was low in this study, which may preclude a definitive 
appraisal. One further drawback inherent to the design of this study is that only 
patients requiring treatment were included, which may select against HIV ‘elite 
suppressors’. 
Importantly, the impact of Bw4 on viral load after STI operated 
independently from pretreatment viral loads, indicating a prognostic power 
additional to that of pretreatment set-point viral load. Other factors already known 
to influence viral replication during and after treatment of HIV infection include viral 
‘fitness’ parameters such as its sensitivity to cytokines [27], viral diversity before 
initiation of ART [28], and parameters of humoral immunity such as anti-p24 
antibody titres [8]. Interestingly, neither the quantity nor the quality of HIV-specific 
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CD8 T-cell responses has previously been found to be predictive for the ability to 
control HIV replication after STI [23, 29]. 
In conclusion, we show that the presence of HLA-Bw4 significantly impacts 
on the control of viral load after STI during chronic HIV infection. Whether the 
increased capacity to suppress HIV-1 replication associated with HLA-Bw4 
warrants reappraisal of STI as a treatment option in selected patient populations 
depends on the findings of future studies. 
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Abstract 
 
Patients carrying activating killer cell immunoglobulin-like receptor (KIR) genes are 
significantly protected from cytomegalovirus (CMV)-associated complications after 
solid organ or hematopoietic stem cell transplantation. Whether previous infection 
with CMV affects natural killer (NK)-cell function in healthy donors is unknown.  
We studied the KIR repertoire and alterations of KIR expression after in vitro 
exposure to CMV in 54 healthy donors. The expression of neither activating nor 
inhibitory KIRs was different at baseline between 23 seropositive and 31 
seronegative donors. However, after co-culture of NK-cells with CMV-infected 
fibroblast cells, expression of the inhibitory receptors KIR2DL1 and KIR2DL3 and 
the activating receptor KIR3DS1 significantly increased in CMV-seropositive 
donors. In CMV-seronegative donors, changes were subtle and restricted to the 
subset of NK-cells expressing NKG2C.  Expansion of inhibitory KIRs occurred 
exclusively in donors carrying the cognate HLA class I ligands, whereas the 
presence of the putative ligand HLA-Bw4 was not necessary for the expansion of 
KIR3DS1-expressing NK-cells.  !
Our data show that previous infection with CMV does not alter the resting NK-cell 
receptor repertoire, but appears to modify how NK-cells respond to re-exposure to 
CMV in vitro. 
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Introduction 
 
NK cells are an important component of the immune system in the control of viral 
infection [1]. Unlike B and T cells, NK cells do not display rearranged receptors but 
instead are regulated by the integration of signaling from germline encoded 
activating and inhibitory receptors. One important and incompletely characterized 
family of receptors are the killer cell immunoglobulin-like receptors (KIRs) [2]. KIRs 
are almost exclusively expressed on NK cells and encoded by 15 different gene 
loci, nine inhibitory iKIRs, and six activating aKIRs. The KIR genes cluster in 
chromosome 19, forming haplotypes composed of 7–11 individual KIR genes. The 
most common haplotype in Caucasians contains mostly iKIRs accompanied by a 
single or no aKIR gene and is called “A” haplotype [3]. Haplotypes containing more 
than one aKIR gene are collectively termed “B” haplotypes. Most iKIRs recognize 
HLA class I ligands and function as important receptors in the maintenance of NK-
cell self-tolerance. In contrast, neither the ligands nor the function of most aKIRs 
have been established [4]. 
We have recently shown in patients undergoing solid organ transplantation 
a protective effect of B haplotype genes regarding posttransplant CMV infection 
and reactivation [5, 6]. Similar studies have shown congruent results for donor 
activating KIR genotype in recipients of hematopoietic stem cell transplantation [7, 
8]. These data suggest that NK cells might recognize CMV-infected cells via 
activating KIR receptors. 
Primary CMV infection most frequently occurs subclinically, and no studies 
have so far studied NK cells during primary CMV infection. However, recent 
evidence suggests that murine NK cells may display immunological memory 
comparable to that of B and T lymphocytes [9, 10]. In mice infected with murine 
CMV, the repertoire of Ly49 (the murine homologue of KIR) on NK cells stays 
permanently altered [11]. The potential for CMV to modulate NK-cell surface 
receptors is underlined by the fact that in humans, latent CMV infection has been 
shown to induce permanent up-regulation of the activating NK-cell receptor natural 
killer cell group antigen 2C (NKG2C) [12–14]. Collectively, these data suggest that 
latent CMV infection might lead to changes in the KIR repertoire of NK cells or 
might alter the NK-cell response to CMV in vitro. 
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We therefore assessed in a cohort of healthy donors the expression of 
inhibitory and activating KIR receptors. KIR repertoire was assessed both in 
freshly collected NK cells as well as after co-culture with a CMV-infected fibroblast 
cell line. 
 
Materials and methods 
 
Healthy donor buffy coats and sera were collected under an ethical committee 
approved protocol after written informed consent from all study participants. 
PBMCs were extracted by using Ficoll. IgG antibodies as a sign of previous 
infection with CMV were detected using a commercially available assay (Architect 
CMV IgG, Abbott). DNA was extracted from an aliquot of cells by NucleoSpin DNA 
Extraction Kit (Macherey-Nagel, Düren, Germany), and stored at −20°C until use. 
The remaining mononuclear cells were cryopreserved until use as described 
below. 
 
Antibodies and flow cytometry 
 
mAbs used to stain cell-surface and intracellular Ags were: CD3 (OKT3, 
eBioscience), CD56 (HCD56, BioLegend), KIR2DL1 (143211, R&D), KIR3DL1 
(DX9, Miltenyi), KIR2DL3 (180701, R&D), KIR2DL1/DS1 (HP-MA4, BioLegend), 
KIR3DL1/S1 (Z27.3.7, Beckman Coulter), NKG2A (Z199.1, Beckman Coulter), 
NKG2C (134591, R&D Systems), KIR2DS4 (JJC11.6, Miltenyi), KIR2DL5 (UP-R, 
BioLegend), KIR2DL2/S2/L3 (DX27, Miltenyi), Ki-67 (20Raj1, eBioscience), 
CD107a (H4A3, BD- Pharmingen), and IFN-γ (B27, BD Pharmingen). Samples 
were acquired on a DAKO CyAn ADP nine-color flow cytometer (Beckman 
Coulter). For all analyses of NK-cell subsets, we gated on the CD56+/CD3- 
subset. FACS plots were analyzed with FlowJo software version 9.2. Propidium 
iodide (BD Pharmingen) was used to exclude dead cells from the analysis. 
 
CMV co-culture 
 
Healthy donor PBMCs (0.2 × 10
6
) were cultured in the presence of 5000 MRC-5 
fetal human lung fibroblast cells (kindly provided by H. Hirsch, Basel) on 96-well 
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plates in 200 µL of DMEM plus L-glutamine, 1 mg/mL D-glucose and pyruvate 
(GIBCO), 10% FCS (Sigma-Aldrich), and 1000 U penicillin/streptomycin (GIBCO). 
Cells were cultured at 37°C for 14–21 days, and half of the co- culture medium 
was replaced weekly. At indicated days, cells were harvested and analyzed by 
FACS for analysis of KIR and NKG2A expression. The MRC-5 cell line was 
infected with a WT strain of CMV (kindly provided by H. H. Hirsch, Basel) the day 
before culture and also weekly during the changing of culture medium. Co-culture 
with uninfected MRC-5 was used as a negative control. Successful infection of 
MRC-5 cells by CMV was assessed in control cultures demonstrating cytopathic 
effects. 
 
Genotyping and quantitative PCR 
 
KIR genotype was assessed using sequence-specific primer PCR [25]. Known 
ligands for inhibitory KIR were typed by PCR-sequence-specific primer (HLA-C1 
group versus HLA-C2 group), and by using a real-time PCR method that detects 
HLA-Bw4 ligands [26, 27]. For quantitative PCR, NK cells were purified from 
PBMCs using the NK-Cell Isolation Kit (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany). RNA was extracted from purified NK cells (NucleoSpin RNAII, 
Macherey-Nagel) and reverse transcribed by High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA) according to 
manufacturer’s protocol. The real-time PCRs were performed by Applied 
Biosystems 7500 Real-Time PCR System in 10 µL reaction mixture volumes 
containing 1× Power SYBR Green I Master Mix (Applied Biosystems, Warrington, 
UK), 0.3 µM of KIR-specific primers [25] or 0.3 µM housekeeping gene (GAPDH) 
(Forward: 5’-GAC CCC TTC ATT GAC CTC AAC TAC A-3’) Reverse: 5’-CTA AGC 
AGT TGG TGG TGC AGG-3’) and 1 µL of postreverse-transcription mixture. PCR 
cycling conditions were set to 2 min at 50°C and 10 min at 95°C followed by 50 
cycles of 15 s at 95°C and 1 min at 60°C. The melting curve stage was added to 
the program in order to control samples’ quality. 
 
Statistics 
 
Resting KIR repertoire expression was compared between CMV-seropositive and -
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seronegative donors by unpaired t-test. KIR expression after CMV co-culture was 
compared by paired t-test in samples exposed to CMV versus cells from the same 
donor cultured in the absence of CMV. All p-values presented are two-sided and 
were considered significant if < 0.05. 
 
Results 
 
NK-cell inhibitory and activating KIR repertoire is not altered by CMV 
infection 
 
Fifty-four healthy donors were genotyped for the non-framework genes 2DL1, 
2DL2, 2DL3, 2DL5, 3DL1, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, and 3DS1. KIR gene 
frequencies were comparable in 23 CMV-seropositive and 31 seronegative donors 
and within the range of published prevalences for Caucasian donors (data not 
shown). The expression of cell surface inhibitory (2DL1/CD158a, 2DL2/3/CD158b, 
2DL5/CD158f, 3DL1/CD158e1) and activating (2DS1/CD158h, 2DS4/CD158i, 
3DS1/CD158e2) KIRs by flow cytometry was equally comparable between CMV-
seronegative and CMV-seropositive patients (Supporting Information Fig. 1A–E, H 
and J). No antibodies are available against KIR2DS3 and KIR2DS5, and all 
antibodies that detect KIR2DS2 cross-react with the inhibitory isoform KIR2DL2. 
We therefore used quantitative PCR to compare the expression of these receptors 
in purified NK cells from CMV-seropositive and -seronegative donors. Again, no 
significant differences were detected between CMV-seropositive and CMV-
seronegative donors for KIR2DS2, KIR2DS3, or KIR2DS5 (Supporting Information 
Fig. 1F, G and I). 
Previous data demonstrated the expansion of NK cells expressing the 
activating receptor NKG2C in CMV-seropositive donors [13]. To assess whether 
NK cells expressing activating KIR receptors are enriched within the NKG2C 
subset, we analyzed co-expression of KIR2DS1 and KIR3DS1 with NKG2C on NK 
cells. In agreement with previous studies, we found higher expression of NKG2C 
in seropositive donors. However, co-expression of NKG2C with activating 
KIR2DS1 and KIR3DS1 was not different in CMV-seropositive or -seronegative 
donors (data not shown). Collectively, these data show that the resting NK-cell KIR 
repertoire is not modulated by previous CMV infection. 
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NK cells expressing KIR2DL1, 2DL3, and 3DS1 expand after CMV co-culture 
in CMV-seropositive donors 
 
We next assessed how NK-cell subsets respond to in vitro exposure to CMV using 
a co-culture model using the fibroblast line MRC-5 (which supports CMV 
replication in vitro and carries all relevant ligands to inhibitory KIRs, that is, HLA 
groups C1, C2, and Bw4) in the presence or absence of CMV. In both CMV-
seropositive and CMV-seronegative donors, the frequency of NK cells within the 
PBMC population increased during CMV co-culture (day 0: 8 and 6%, day 21: 17 
and 20%, respectively, for seropositive and seronegative donors). Compared with 
non-infected MRC-5, co-culture with CMV-infected MRC-5 induced specific 
changes in the KIR repertoire (Fig. 1). KIR repertoire changes on the total NK-cell 
population were exclusively detected in CMV-seropositive donors. The frequency 
of NK cells expressing the inhibitory receptors KIR2DL1, KIR2DL2/3, and natural 
killer cell group antigen 2A (NKG2A) increased significantly in PBMCs co-cultured 
with CMV-infected MRC-5 cells (Fig. 1A, B, and D), if NK cells were derived from a 
donor carrying anti-CMV-IgG antibodies. No expansion of KIR3DL1 was observed 
(Fig. 1C). Strikingly, no expansion of KIR2DL1 and KIR2DL2/3 expressing NK 
cells occurred in CMV-seronegative donors upon co-culture on CMV-infected 
MRC-5. Of the activating receptors studied, we found no significant change in the 
expression of KIR2DS1 (Fig. 1E), whereas the frequency of KIR3DS1-expressing 
NK cells increased significantly after co-culture with CMV-infected MRC-5 (Fig. 
1F). This was exclusively observed if the donor had previously undergone CMV 
infection. Importantly, both in CMV-seropositive and CMV-seronegative donors, 
NK cells were polyclonal after co-culture, as evidenced by a variegated pattern of 
KIR and NKG2A expression. In CMV-seronegative donors, the only alteration 
induced by CMV infection was an increase in the expression of NKG2A by day 21. 
As NKG2C expression has previously been shown to be up-regulated in 
patients during and after CMV replication [13,15,16], we assessed total NKG2C 
expression and KIR expression on NKG2C+ cells before and after 14-day culture, 
as a more sensitive assay directly investigating putative CMV-specific NK cells. 
NKG2C expression was nonsignificantly elevated in CMV-seropositive donors 
compared with that in seronegative donors at baseline. After culture, we detected 
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a significant increase in NK-cell NKG2C expression, if PBMCs were cultured on 
infected compared with culture on non-infected MRC-5, which was restricted to 
CMV-seropositive patients (Fig. 2A). Confirming results obtained on total NK cells, 
expression of KIR2DL1 but not of KIR3DL1 increased on NKG2C+ cells (Fig. 2C 
and D). Interestingly, a small but statistically significant increase in KIR2DL1 on 
NKG2C+ was detected also in CMV-seronegative donors; however, this increase 
was much smaller than that seen in CMV-seropositive donors (Fig. 2C). 
To discriminate between expression of KIR2DL2/S2 and KIR2DL3, we next 
cultured PBMCs from donors carrying the genes for all three receptors. Co-
staining of a KIR2DL3 specific Ab with an Ab recognizing KIR2DL2/S2/L3 allowed 
us to distinguish between expression of KIR2DL2/S2 and KIR2DL3 (Fig. 3A). In 
five CMV-seropositive donors, strong expansion of KIR2DL3-expressing NK cells 
was documented, while co-culture with CMV-infected fibroblasts had no impact on 
the expression of KIR2DL2/S2 (Fig. 3B and C). 
To address whether the increased expression of KIR-expressing cells 
represents true expansion, we determined cell number weekly during the 21-day 
co-culture with MRC-5 in the presence or absence of CMV. The NK-cell number 
contracted during the first week, followed by an expansion of NK cells exclusively 
in seropositive donors in the presence of CMV (Supporting Information Fig. 2). 
Staining for the proliferation marker Ki-67 corroborated these results: infection of 
MRC-5 with CMV led to a massive up-regulation of Ki-67 on NK cells if these 
stemmed from CMV-seropositive donors (Fig. 2B). Interestingly, when the KIR 
repertoire was assessed on Ki-67+ cells, we noted expansion of KIR2DL1/Ki-67 
double positive but not of KIR3DL1/Ki-67 double positive cells after co-culture with 
CMV-infected MRC-5 (Fig. 2E and F). 
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Figure 1. Changes to the NK-cell KIR repertoire after co-culture with CMV-infected fibroblasts. 
PBMCs from CMV-seropositive or negative donors were co-cultured for 21 days with CMV-infected 
fibroblasts and the percentage of (A) KIR2DL1-, (B) KIR2DL2/3-, (C) KIR3DL1-, (D) NKG2A-, (E) 
KIR2DS1- and (F) KIR3DS1-expressing cells within the total NK-cell population were determined 
by gating on CD56+/CD3– cells and then for individual KIRs. Data are shown as mean + SEM of 24 
donors pooled from 6 experiments. Comparison between groups was made by Student’s T-test, * p 
< 0.05. 
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Expansion of inhibitory KIR-expressing NK cells is dependent on the 
presence of KIR ligands 
 
We next aimed to characterize factors influencing the expansion of KIR-expressing 
NK cells. HLA-C1 group Ags are the ligand for KIR2DL2/S2/L3, while HLA-C2 
group Ags are the ligands to KIR2DL1 [17]. If CMV-seropositive donors were 
stratified according to their KIR ligand status, an expansion of KIR2D-expressing 
NK cells occurred only in the presence of the cognate KIR ligand: KIR2DL1 
expanded only in donors carrying a C2 ligand (Fig. 4A and B), whereas 
KIR2DL2/S2/L3 NK cells expanded exclusively in the presence of the cognate 
group C1 ligand (Fig. 4C and D). 
While no ligand has been identified for the activating KIR receptor KIR3DS1 
[18], genetic association studies have suggested an epistatic interaction of 
KIR3DS1 with HLA-Bw4 in HIV infection [19]. Analysis of Bw4-status in 
conjunction with KIR3DS1 expression in our population showed that expansion of 
KIR3DS1 occurred irrespective of the presence of Bw4 (day 21 KIRDS1 
expression in CMV-exposed versus CMV non-exposed cells in seropositive 
donors: mean 23 versus 8% in Bw4-negative, and 31 versus 11% in Bw4-positive 
donors, p < 0.05 for both comparisons). 
 
Increase in inhibitory KIR expression is due to expansion of KIR+ cells 
 
To address the question, whether the increase in KIR expression induced by 
exposure to CMV was due to expansion of NK cells expressing KIRs at the 
initiation of co-culture or due to induction of KIRs in initially KIR- NK cells, we 
depleted PBMCs of NK cells expressing either KIR2DL1 or KIR2DL3. After co-
culture with CMV-infected MRC-5, NK cells remained negative for KIR2DL1 and 
KIR2DL3, demonstrating that the increase in expression of the respective KIR was 
most likely due to expansion of KIR+ NK cells rather than induction of KIR 
expression in KIR- NK cells (data not shown). As KIR3DS1 expression is 
detectable only barely above background staining on primary NK cells [20], flow 
cytometric sorting of KIR3DS1+ from KIR3DS1- cells was not possible, and formal 
proof that the increase in KIR3DS1 detected after exposure to CMV is still lacking. 
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Figure 2. Changes in NKG2C and Ki-67 expression after NK-cell co-culture with CMV-infected 
fibroblasts. PBMCs from CMV-seropositive or seronegative donors were co-cultured for fourteen 
days with CMV-infected fibroblasts and the frequency of (A) NKG2C expression, and (B) Ki-67 
expression was measured on NK-cells after gating on CD56+/CD3– cells. (C-F) Similarly, (C, E) 
KIR2DL1 and (D, F) KIR3DL1 expression was assessed within NKG2C+ and Ki-67+ cells 
respectively. Data are shown as mean + SEM of 20 donors pooled from 2 experiments. 
Comparison between groups was made by Student’s T-test, * p < 0.05. 
 
Changes in KIR repertoire do not depend on the presence of B- and T-
lymphocytes 
 
To exclude the possibility that changes in KIR repertoire were induced by the 
presence of B- and T lymphocytes, we cultured FACS-sorted NK cells from CMV-
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seropositive donors in the presence of MRC-5 with and without CMV. Changes in 
the KIR repertoire were closely recapitulated by those found if PBMCs were co-
cultured from the same donors, showing that the specific expansion could not be 
ascribed to the presence of lymphocytes other than NK cells in the co-culture 
assay (Supporting Information Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Expansion of KIR2DL3-expressing NK-cells after PBMC co-culture with infected 
fibroblasts. PBMCs from CMV-seropositive donors were co-cultured for 21 days with CMV-infected 
fibroblasts.  (A) A representative flow cytometry plot of the gating strategy for CD56+/CD3– cells is 
shown. (B, C) The percentage of (B) KIR2DL3- and (C) KIR2DL2/S2-expressing NK-cells was 
determined by flow cytometry. Data are shown as mean + SEM of 5 donors pooled from two 
experiments. Comparison between groups was made by Student’s T-test, * p < 0.05. 
 
CMV infection leads to degranulation and cytokine production by NK cells 
 
In order to assess how NK cells respond functionally to exposure to CMV infected 
target cells, we assessed CD107a expression as a marker of degranulation and 
IFN-γ production by intracellular cytokine staining. After two and 3 weeks of 
culture, all NK-cell subsets of CMV-seropositive and -seronegative donors 
exposed to CMV in vitro degranulated and produced IFN-γ at the level of positive 
controls (PMA), suggesting nonspecific activation (data not shown). When 
analyzed earlier, we detected a significant increase in degranulation and IFN-γ 
production in CMV-exposed NK cells already at 3 days of co-culture. Extending 
previous results, degranulation and cytokine production were stronger in CMV-
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seropositive than in CMV-seronegative donors, and were significantly higher for 
the HLA-C binding KIR2DL1 than for the HLA-B binding KIR3DL1 (Fig. 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Expansion of KIR2DL1 and KIR2DL2/3-positive NK-cells in relationship to the presence 
of HLA KIR ligands. PBMCs from CMV-seropositive or -seronegative donors were co-cultured for 
21 days with CMV-infected fibroblasts and the percentage of (A, B) KIR2DL1- and (C, D) 
KIR2DL2/3-positive NK-cells was determined in patients, which did (A, C) or did not (B, D) carry 
the KIR ligands HLA-C1 and HLA-C2 respectively. Data are shown as mean + SEM of 5-11 donors 
pooled from 2 experiments. Comparison between groups was made by Student’s T-test, * p < 0.05. 
 
Discussion 
 
This analysis of the impact of previous infection with CMV on the KIR repertoire of 
NK cells was prompted by the observation that transplant recipients are relatively 
protected from CMV replication if they carried B-haplotype associated activating 
KIR genes [5–8]. In our most recent analysis, protective effects were most evident 
in carriers of activating KIR genes located in the telomeric part of the KIR 
haplotype [6]. This part of the KIR gene cluster contains the activating receptors 
KIR2DS1, KIR3DS1, and KIR2DS5. The strong linkage disequilibrium between 
these genes makes it unlikely that population-based genetic association studies 
will be helpful in further identifying the resistance locus [21]. We there- fore aimed 
in this study to analyze if previous infection with CMV alters the repertoire of KIR 
expression both in freshly isolated cells as well as after exposure to CMV in an in 
vitro co-culture model. 
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In agreement with previous data investigating NK-cell receptor repertoire of 
CMV-seropositive and -seronegative donors, we find no evidence that the KIR 
repertoire of resting NK cells is altered by previous infection with CMV [12, 14]. In 
contrast, significant alterations in the KIR repertoire occurred after exposure of NK 
cells to CMV in vitro. We observed a specific expansion of NK cells expressing the 
inhibitory receptors KIR2DL1, KIR2DL3, and NKG2A, as well as of NK cells 
expressing the activating receptor KIR3DS1. Expansion of KIR2DL1 and KIR2DL3 
occurred only in the presence of the cognate HLA-C ligands, whereas KIR3DS1+ 
NK cells expanded independently from the presence of the putative ligand HLA-
Bw4. 
Our results are intriguing in several ways: regarding the aKIR-mediated 
protection, we show that of the aKIR receptors to which antibodies exist, KIR3DS1 
is the only one to expand in response to stimulation with CMV. This is in 
agreement with our population-based studies, which localized the locus of 
resistance to the telomeric part of the KIR haplotype, which contains — among 
other KIR receptor genes — the gene coding for KIR3DS1 [6]. Interestingly, 
expansion of KIR3DS1-expressing cells is irrespective of the presence of the 
putative KIR3DS1-ligand HLA-Bw4, suggesting that KIR3DS1 might bind a ligand 
outside of the context of HLA. Potential candidate ligands, which will need to be 
investigated in the future, may include UL18, a CMV-encoded HLA-like decoy 
protein, which has previously been shown to bind the inhibitory receptor LIR-1 
[22]. 
Strikingly, NK cells expressing the inhibitory receptors KIR2DL1, KIR2DL3, 
and NKG2A were also found to expand in response to in vitro exposure to CMV. 
KIR2DL1 and KIR2DL3 bind mutually exclusive subsets of HLA-C Ags, whereas 
HLA-E is the ligand for NKG2A. The notion that a receptor conveying an inhibitory 
signal leads to expansion of cells expressing the receptor might appear unintuitive. 
However, recent studies have revealed that the inhibitory KIR/HLA interaction may 
be disrupted by peptides antagonizing the binding of KIRs to cognate HLA [23]. 
Whether such “peptide antagonism” is indeed responsible for the expansion of NK 
cells carrying inhibitory receptors will need to be addressed in future experiments. 
Finally, the changes of NK-cell receptor repertoire in response to exposure 
to CMV occurred almost exclusively in patients with previous exposure to CMV, as 
measured by CMV IgG seropositivity. Only in a sensitive analysis gating first on 
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NKG2C+ cells, were we able to also document an up-regulation of HLA-C binding 
KIRs in CMV-seronegative donors. While NK cells are traditionally seen as innate 
immune cells without the capacity for memory formation, recent studies in mice 
have suggested that NK cells share many features with effector cells of adaptive 
immunity, including the capacity to elicit memory responses [10, 24]. Whether the 
fact that changes in the NK-cell repertoire after in vitro expo- sure to CMV truly 
represent a function of NK-cell memory to human CMV cannot be concluded with 
certainty, as CMV persists latently in infected patients, and might chronically 
stimulate NK cells. 
In conclusion, we show that receptor repertoire of circulating NK cells is not 
altered by previous infection with CMV. After exposure to CMV in vitro, however, 
an HLA class I ligand dependent expansion of KIR2DL1+ and KIR2DL3+ cells 
occurs, along with expansion of cells expressing NKG2A and KIR3DS1. Changes 
to the NK-cell receptor repertoire were confined to CMV-IgG positive patients. 
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Figure 5. Functional analysis of NK-cells in PBMCs cultured for three days in the presence of 
MRC-5 with or without CMV. PBMCs from CMV-seropositive or -seronegative donors were co-
cultured for 3 days with fibroblasts infected or not with CMV. (A, C, E) Surface CD107a expression 
and (B, D, F) intracellular expression of IFN-gamma was assessed by gating on (A, B) CD56+/CD3- 
NK-cells and within NK-cells expressing (C, D) KIR2DL1 and (E, F) KIR3DL1. Data are shown as 
mean + SEM of 5 donors pooled from 2 experiments. Comparison between groups was made by 
Student’s T-test, * p < 0.05. 
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Supporting Information Figure 1.  NK cell KIR and NKG2A expression in CMV- seropositive and 
seronegative donors. PBMCs from CMV-seropositive (CMV+) or CMV-seronegative (CMV-) donors 
were stained for cell surface expression of the inhibitory receptors (A) KIR2DL1, (B) KIR2DL2/3, 
(C) KIR2DL5, (D) KIR3DL1 and of the activating receptors (E) KIR2DS1, (H) KIR2DS4, and (J) 
KIR3DS1 after gating on CD56+/CD3- NK cells. mRNA quantity was compared for the activating 
receptors KIR2DS2, KIR2DS3, and KIR2DS5 in immunomagnetically sorted NK cells by qRT-PCR. 
Data represent 6 experiments performed in 54 donors. Expression of each KIR is shown only in 
donors that carry the respective KIR gene. Horizontal lines represent means. Comparison between 
groups was made by Student’s T-test. 
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Supporting Information Figure 2. Expansion of NK cells after co-culture with CMV- infected 
fibroblasts. Total number of NK cells derived from CMV-seropositive (CMV+) and CMV 
seronegative donors (CMV-) was assessed during three-week culture in the presence of the 
fibroblast cells infected or not (control) with CMV by a combination of trypan blue cell counting and 
FACS phenotyping. Data are pooled from 2 experiments involving a total of 10 donors. Bars 
represent means and whiskers the standard error of the mean. Comparison between groups was 
made by Student’s T-test. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Supporting Information Figure 3. Expression of KIR and NKG2A in FACS-sorted NK cells co-
cultured with CMV-infected fibroblasts. FACS-sorted NK cells from CMV-seropositive donors were 
co-cultured for 21 days with fibroblasts in the presence or absence of CMV and the expression of 
inhibitory KIR- and NKG2A receptors was compared by flowcytometry in cultured samples. Data 
are pooled from 2 experiments involving a total of 5 donors. Bars represent means and whiskers 
the standard error of the mean. 
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Abstract 
 
Analysis of killer cell immunoglobulin-like receptor (KIR) expression has been 
notoriously difficult because of the cross-reactivity of available antibodies, in 
particular between activating and inhibitory isoforms. We undertook a 
comprehensive study of available anti-KIR antibodies binding to activating KIRs (a-
KIRs). Using cell lines stably transfected with a-KIRs (KIR2DS1–S5 and 
KIR3DS1), we confirmed documented binding specificities. In addition, we show 
that clones HPMA4 and 143211—previously assumed to be specific for 
KIR2DS1/L1 and KIR2DL1, respectively—bind KIR2DS5 and KIR2DS3 (HPMA4), 
and KIR2DS5 (143211). Other antibodies with previously undocumented binding 
were JJC11.6 (recognizing KIR2DS3) and 5.133 (recognizing all a-KIRs except 
KIR2DS1 and KIR2DS3). The novel KIR2DS5 reactivities were confirmed by 
blocking with soluble KIR-Fc fusion proteins, and by reverse transcriptase-PCR 
analysis of sorted primary natural killer cells. In conclusion, we show formerly 
undocumented binding properties of anti-KIR antibodies. These cross-reactivities 
should be taken into account when analyzing KIR expression. 
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Introduction 
 
The expression of killer immunoglobulin-like receptors (KIRs) on the surface of 
natural killer (NK) cells presents considerable interindividual variability [1]. 
Variation in KIR gene content [2], KIR allelic polymorphism [3, 4], clonal 
variegation of the NK-cell repertoire [5], and other factors such as subclinical 
infection [6], all account for phenotypical diversity of NK-cell repertoires, which 
differ even among individuals with identical KIR genotype. Together with the 
extensive polymorphism of human leukocyte antigen alleles, many of which 
encode KIR ligands, this variability shapes host immune responses that depend on 
the interaction between KIRs and the human leukocyte antigen in a highly 
personalized manner [7]. An accurate phenotypic picture of the NK-cell KIR 
repertoire can thus be a valuable tool in forecasting individual susceptibility to 
auto- immune disease or viral infection, or the graft versus leukemia effect 
observed in some types of hematopoietic stem cell transplantation [8]. 
Unfortunately, the specificity of antibodies to detect KIR surface expression 
on NK cells is not absolute, owing to the high ectodomain homology among 
different KIR proteins. In particular, the cross-reactivity of antibodies recognizing 
both the inhibitory and activating members of the KIR family has hampered a 
complete and precise phenotypical analysis of the KIR repertoire [9]. In addition, 
the reactivity of some anti-KIR antibodies currently used in flow cytometry remains 
incompletely characterized, due in part to the redefinition of KIR alleles and 
antibody specificities [10, 11]. We undertook this study to systematically assess 
the reactivity of commercially available anti-KIR antibodies with activating KIR (a-
KIR) molecules using transfected NK cell lines. 
 
Materials and Methods 
 
NK cell transfectants 
 
Complementary DNA for all the known human a-KIR genes were obtained by 
reverse transcriptase-PCR from peripheral blood mononuclear cell of donors 
genotyped by single specific primer-PCR [20]. The entire coding region, including 
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the leader peptide, of the most prevalent allele of each a-KIR gene (KIR2DS1*002, 
KIR2DS2*001, KIR2DS3*001, KIR2DS4*001, KIR2DS5*002 and KIR3DS1*013), 
was cloned and inserted into the retroviral vector pMX-Puro (a generous gift from 
Professor L. Lanier, UCSF, USA). Cloned plasmids were sequenced bidirectionally 
and aligned to KIR sequences using the current IPD-KIR database 
(http://www.ebi.ac.uk/ipd/kir/). Each KIR–pMX construct was transfected into 
packaging Phoenix A cells (gift from L. Lanier) and viral supernatants used to 
transduce NKL cells, an NK cell line lacking a-KIR expression (gift of Dr. AM 
Garcia-Lora, University Hospital Virgen de las Nieves, Granada, Spain) and 
transduced NKL cells were selected in 0.5 mg ml-1 puromycin. NK cells expressing 
a-KIR were grown in RPMI (Invitrogen, Carlsbad, CA, USA) supplemented with 
10% human AB serum and 100 U ml-1 rhIL-2 (Proleukin, Novartis, Basel, 
Switzerland). Owing to the low expression of 2DS3 and 3DS1, additional 
transfections were performed with these KIRs in the NK cell line YT. 
 
Flow cytometry  
 
To test the reactivity of the panel of antibodies shown in Supplementary Table 1 
against the different a-KIRs, between 5x104 and 105 transfected NK cells were 
incubated with each antibody in FACS buffer (2% FCS in phosphate buffered-
saline), washed, stained with a viability dye (Sytox blue, Invitrogen) and analyzed 
on a Cyan ADP Beckman-Coulter flow cytometer (Beckman Coulter, Brea, CA, 
USA). The anti-KIR antibodies were purchased commercially from the vendors 
listed in Supplementary Table 1, used at saturating concentrations. Other 
antibodies used were anti-CD3 (clone SK7), CD14 (clone 61D3) and CD19 (clone 
HIB19, all from eBioscience, San Diego, CA, USA) and CD56 (clone HCD56, 
Biolegend, San Diego, CA, USA). Antibody isotope controls were used in parallel, 
and non-viable cells were excluded from the analysis. Intracellular staining was 
done similarly after a short fixation step (15 min) and using permeabilization buffer 
(Biolegend) instead of FACS buffer, following the manufacturer’s protocol. 
 
Production of recombinant KIR-Fc fusion proteins 
 
Baculoviral constructs encoding the ectodomains of 2DS1, 2DS2, 2DS3, 2DS4 
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and 2DS5 in frame with the CH2 and CH3 domains of human IgG1 (Fc region) 
were kindly provided by P. Parham (Stanford University, USA). As revealed by 
sequencing, these a-KIR alleles were the same as those used in the cell 
transfectants. The constructs were subcloned into pFL [21] and transfected by 
electroporation into packaging DH10EMBacYFP cells to obtain bacmid DNA. After 
confirming integrity and frame by sequencing, 2 mg of bacmid DNA was 
transfected with Cellfectin (Invitrogen) into Sf21 cells to obtain baculovirus 
supernatant V0. Two rounds of amplification followed to ensure high titer virus 
supernatants (V2), which were then used for recombinant protein production in a 
serum-free culture medium (SF-4 Baculo Express, Bioconcept, Allschwil, 
Switzerland) at 27°C. KIR-fusion proteins were purified by protein A-sepharose 
affinity chromatography and analyzed by polyacrylamide gel electrophoresis. For 
blocking experiments, staining of KIR transfectants with a test antibody was 
performed either in the absence or after pre-incubation of the antibody with each 
of the KIR-Fc fusion proteins at 100 mg ml-1 for 30 min at room temperature. 
 
NK-cell sorting and reverse transcriptase-PCR for KIRs  
 
Peripheral blood mononuclear cells were stained sequentially with the HPMA4 
antibody for 30 min (1:50 dilution), followed by an overnight incubation with the 
EB6b antibody (1:50 dilution) or with 143211 exclusively in FACS buffer and an 
antibody cocktail consisting of anti-CD3, CD14, CD19 and CD56 antibodies for 
NK-cell gating. The different cell subpopulations obtained in donors with either 
KIR2DS5+ or KIR2DS5- genotype were sorted by FACS with an Aria cell sorter 
(BD Biosciences, San Jose, CA). Each sorted subset was immediately processed 
for RNA extraction with the Reliaprep kit (Promega, Madison, WI, USA) and 
reverse transcription (High-Capacity cDNA Reverse Transcription kit, Applied 
Biosystems-Life Technologies, Carlsbad, CA, USA). Intron-spanning primers used 
in previous studies [20, 22] were used to amplify KIR2DL1 (F: 5’-GCA G CA CCA 
TGT CGC TCT T-3’; R: 5’-CCT GCC AGG TCT TGC G-3’), KIR2DS1 (F: 5’-TCT 
CCA TCA GTC GCA TGA A-3’; R: 5’-TTA TGC GTA TGA CAC CTC CTG ATG-3’) 
and KIR2DS5 (F: 5’-AGA GAG GGG ACG TTT AAC C-3’; R: 5’-CAA GCA GTG 
GGT CAC TTG A-3’) by quantitative PCR using a conventional master mix 
(Promega). PCR products were run by agarose electrophoresis to confirm 
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amplicon size. 
 
Results and discussion 
 
Published results have shown that the NKL cell line is devoid of surface KIR 
expression except KIR2DL4 [12]. In agreement with these data, none of the anti-
KIR antibodies tested stained parental NKL cells, with the exception of the 
KIR2DL4 antibody Mab33, showing weak reactivity. NKL cells transfected with 
KIR2DS1, KIR2DS2, KIR2DS4 and KIR3DS1 were stained with monoclonal 
antibodies known to have affinity for these KIRs (clones EB6b, DX27, FES172 and 
Z27, respectively). As no specific antibodies for KIR2DS3 and KIR2DS5 are 
commercially available, cells transfected with these KIRs were positively identified 
with a pan-KIR2D MAb (clone NKVFS1). Flowcytometric characterization of the 
transfected NK cell lines is summarized in Figure 1a. Of note, expression of 
KIR2DS3 was low and mostly intracellular, in agreement with previous reports 
showing that this KIR is retained in the cytosol in transfected cell lines [13]. 
Surface expression of KIR3DS1 was weak in comparison with the other a-KIR 
genes, but comparable to the expression of this KIR gene on primary NK cells, or 
in transfected BaF3 cells [14]. The intracellular and low expression, respectively, of 
KIR2DS3 and KIR3DS1 was similar in the YT cell line. 
Each anti-KIR antibody stained the corresponding a-KIR transfectant and 
not the others as predicted, but some unexpected stainings were observed. Most 
remarkably, antibodies with nominal specificity for KIR2DL1/2DS1 (clone HPMA4) 
and anti-KIR2DL1 (clone 143211) consistently stained cells transfected with 
KIR2DS5. In contrast, another antibody against KIR2DL1/2DS1 (clone EB6b) did 
not show any reactivity against KIR2DS5 (Figure 1b). The HPMA4 antibody also 
stained the KIR2DS3 transfectants (Figure 1b) after intracellular staining, although 
the low expression of this KIR led to stainings of lower intensity, in both NKL and 
YT transfectants. Other anti-KIR antibodies showing unexpected cross-reactivities 
were clone JJC11.6 (anti-KIR2DS4), against KIR2DS3 in intracellular staining 
experiments, and clone 5.133 (anti-KIR3DL1/3DL2), which cross-reacted with all 
transfected cell lines except those expressing KIR2DS1 and KIR2DS3 (Figures 1c 
and d). 
To confirm the reactivity of the HPMA4 and 143211 antibodies with 
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KIR2DS5, and to more conveniently assess the cross-reactivity of these antibodies 
against KIR2DS3, we used recombinant a-KIR-Fc fusion proteins in blocking 
experiments. Each KIR-Fc protein blocked the staining of the corresponding 
transfectant with its identifying antibody, indicating correct folding of the Fc fusion 
proteins. For example, the KIR2DS1-Fc fusion abrogated staining of KIR2DS1 
transfectants by the HPMA4 antibody, and while the KIR2DS2-Fc and KIR2DS4-
Fc did not affect staining by this antibody, pre-incubation with the KIR2DS3- or the 
KIR2DS5-Fc fusion proteins completely blocked it (Figure 1e). A similar 
experiment was conducted using KIR2DS5 transfectants and showed identical 
results, confirming that the D1 and D2 domains of KIR2DS3 and KIR2DS5 are 
recognized by the HPMA4 antibody (Figure 1e). Additionally, the reactivity of 
KIR2DS5 transfectants against the 143211 antibody could be totally reversed by 
pre-incubation with KIR2DS5-Fc fusion proteins, also confirming the interaction of 
this antibody with KIR2DS5. In contrast, the very weak staining of 2DS3 
transfectants by 143211 (Figure 1b) could not be confirmed in this assay using 
blocking by KIR2DS3-Fc (Figure 1e). 
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Figure 1. (a) NK cells transfected with a-KIRs (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5 
and KIR3DS1). Histograms show staining of the a-KIR-transfected NK cells (solid line) stained 
each with the corresponding anti-a-KIR antibody (see text for details), along with isotype antibody 
controls, represented by filled gray histograms. Staining for KIR2DS3 is shown with (solid line) and 
without (dashed line) cell permeabilization. (b) The monoclonal antibody HPMA4 stains NKL cells 
transfected with KIR2DS3 (permeabilized) and KIR2DS5; 143211 stains KIR2DS5 and very weakly 
stains KIR2DS3 (permeabilized); whereas EB6b does not stain either KIR2DS3 or KIR2DS5. (c) 
The KIR2DS4 antibody JJC11.6 stains KIR2DS3 transfectants (permeabilized). (d) The 
KIR3DL1/3DL2 5.133 Mab stains KIR2DS2, KIR2DS4, KIR2DS5 and KIR3DS1 transfectants. (e) 
Staining of NKL2DS1 or NKL2DS5 transfectants with different antibodies in the presence of 
different KIR-Fc conjugates. Staining of KIR2DS1-transfected NK cells with the KIR2DL1/2DS1 
antibody HPMA4 is blocked after pre-incubation of the antibody with KIR2DS1-Fc-, KIR2DS3-Fc- 
or KIR2DS5-Fc-chimeras (100 mg ml-1), but not with similar concentrations of KIR2DS2-Fc- or 
KIR2DS4-Fc-chimeras (upper row). Similar results were observed with HPMA4 antibody staining of 
KIR2DS5 transfectants (middle row). Staining of KIR2DS5 transfectants with the 143211 antibody 
is blocked by pre-incubation with KIR2DS5-Fc-chimeras only (lower row). 
a" 2DS1" 2DS2" 2DS3" 2DS4" 2DS5" 3DS1"
EB6b" DX27" NKVFS1" FES172" NKVFS1" Z27"
KIR"
Clone"
b"
HP>MA4" 143211" EB6b"Clone"
2DS5" 2DS5"KIR" 2DS3" 2DS3" 2DS3"
HP>MA4" 143211" EB6b"
c" 2DS3"
JJC11.6"
3DS1"2DS2" 2DS4" 2DS5"d"
2DS5"
2DS1>Fc" 2DS2>Fc" 2DS3>Fc" 2DS4>Fc" 2DS5>Fc"
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We additionally investigated whether the differential staining properties of 
the HPMA4 and EB6b antibodies could be exploited to identify surface expression 
of KIR2DS5 in peripheral blood NK cells. A group of peripheral blood mononuclear 
cell samples from donors genotyped as positive (n=8) and negative (n=7) for 
KIR2DS5 were double-stained sequentially with these antibodies. Using this 
strategy, a cell subpopulation of NK cells compatible with KIR2DS5 surface 
expression was observed (Figure 2a). In all KIR2DS5+ donors, a discrete subset 
of HPMA4+ EB6b- cells was found, amounting to 2–10% of the total NK cells, in 
contrast with KIR2DS5- donors, in whom it was absent. This subset represents 
KIR2DL1- KIR2DS1- KIR2DS5+ cells, but other NK cells may express KIR2DS5 in 
combination with KIR2DL1 and KIR2DS1. This possibility was searched for by 
reverse transcriptase-PCR in sorted cells. As seen in Figure 2b, HPMA4+ EB6b- 
cells expressed the KIR2DS5 transcripts and none of the other two KIRs, but 
KIR2DS5 transcripts were also found in cells expressing KIR2DL1 and KIR2DS1. 
Notably, the staining intensity of KIR2DS1 containing subsets by HPMA4 was 
relatively weak because of sequential staining with HPMA4 followed by EB6b, in 
which the latter antibody competed for binding of HPMA4 (confirmed by sequential 
staining of KIR2DS1 transfectants, data not shown). 
Additionally, in two donors negative for KIR2DL1 and positive for KIR2DS5 
by genotype, we were able to evaluate the total percentage of KIR2DS5 on 
peripheral blood NK cells by staining with the 143211 antibody. Expression of 
KIR2DS5 was detected in 2% and 4% of NK cells, respectively (Figure 2c). The 
identity of this population was confirmed as previously by sorting and reverse 
transcriptase-PCR for KIR2DS5 (Figure 2d). 
In another two donors with a KIR2DS3+ KIR2DS5- genotype, we failed to 
detect intracellular staining by HPMA4 of presumed intracellular KIR2DS3. 
Whether this is due to low expression of KIR2DS3 in primary NK cells, or to the 
specific allele (KIR2DS3*002) in KIR2DS5- individuals [15],  (which was different 
from the more frequent KIR2DS3*001 allele used in transfected cell lines) remains 
unresolved. 
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Figure 2. (a) Representative dot plot showing gated live peripheral blood NK cells double-stained 
sequentially with the HPMA4 (PE) and the EB6b (APC) antibodies in cells from donors with the 
denoted genotype. Only in donors genotyped positive for KIR2DS5 there is a subpopulation of 
HPMA4+ EB6b- stained cells (subpopulation 2). (b) RT-PCR of KIR2DL1, KIR2DS1, KIR2DS5 and 
CD45 (control) of sorted cells corresponding to the cell subsets indicated in (a) and a water control 
(W). Subset 1 does not contain any of the analyzed KIRs, subset 2 contains only KIR2DS5 
transcripts, subset 3 contains only KIR2DL1 transcripts, subset 4 contains a mixture of all the three 
transcripts and subset 5 contains only KIR2DS1 and KIR2DS5. On the right panel, the RT-minus 
control is shown, for example, the same samples were subjected to the reverse transcription 
protocol in the absence of enzyme. (c) Representative dot plot showing gated live peripheral blood 
NK cells stained with the 143211 antibody in cells from a donor with the denoted genotype. In the 
absence of KIR2DL1, the 143211- positive subpopulation 2 includes all the KIR2DS5-positive NK 
cells. (d) RT-PCR of KIR2DS5 and CD45 (control) of sorted cells corresponding to the cell subsets 
indicated in (c) and a water control (W). KIR2DS5 transcripts are only found in population 2. On the 
right panel, the RT-minus control is shown. 
 
Only recently has it been shown that KIR2DS5 is expressed on NK-cell 
surfaces by using a non-commercial antibody [16, 17].  The function of KIR2DS5 in 
NK cells is uncertain at present, as the ligands interacting with it remain unknown, 
although it could potentially modulate the reactivity of NK-cell subsets in certain 
circumstances. The lack of specific antibodies have so far limited the study of 
KIR2DS5, but now its presence and relevance in health and disease can be 
assessed with commercially available antibodies. Likewise, the study of the clonal 
architecture of the NK-cell repertoire can be further refined. The shown cross- 
reactivity with KIR2DS5 could have led in the past to inaccurate estimations of 
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subset frequencies or affected the purity of sorted cells based on the reactivity with 
these antibodies [18].  Importantly, the inheritance of the KIR2DS5 gene is strongly 
linked to that of KIR2DS1 [19]. 
In conclusion, the analysis presented here defines the reactivity of available 
antibodies against the most prevalent a-KIRs. As a major novel finding, clone 
HPMA4 cross-reacts with KIR2DS5 and KIR2DS3. Co-staining of HPMA4 with 
antibodies specific for KIR2DS1/L1 allows detection of surface KIR2DS5 
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Supplementary Table. 
 
    Clone            Nominal specificity Isotype Additional specif. found Vendor 
 HPMA4 ! 2DL1, 2DS1 ! IgG2b 2DS3, 2DS5 Biolegend 
 HP3E4 ! 2DL1, 2DS1, 2DS4 ! IgM - BD 
 EB6b ! 2DL1, 2DS1 ! IgG1 - Beckman 
 11PB6 ! 2DL1, 2DS1 ! IgG1 - Miltenyi 
 143211 ! 2DL1 ! IgG1 2DS5 R & D 
 DX27 ! 2DL2, 2DL3, 2DS2 ! IgG2a - Biolegend 
 CH-L ! 2DL2, 2DL3, 2DS2 ! IgG2b - BD 
 GL183 ! 2DL2, 2DL3, 2DS2 ! IgG1 - Beckman 
 180701 ! 2DL3 ! IgG2a - R & D 
 mAb 33 ! 2DL4 ! IgG1 - Biolegend 
 UP-R1 ! 2DL5 ! IgG1 - Biolegend 
 FES172 ! 2DS4 ! IgG2a - Beckman 
 JJC11.6 ! 2DS4 ! IgG1 2DS3 Miltenyi 
 NKVFS1 ! pan KIR2D ! IgG1 - Miltenyi 
 Z27 ! 3DL1, 3DS1 ! IgG1 - Beckman 
 5.133 ! 3DL1, 3DL2 ! IgG1 2DS2, 2DS4, 2DS5, 3DS1 Miltenyi 
 DX9 ! 3DL1 ! IgG1 - BD 
 
KIR antibodies used in this study. Their established specificities and additional specificities found 
are indicated. 
 
 
K. Czaja                                                             PROJECT 3. 
78  
 
 
 
 
 
 
References 
 
1. Gardiner CM. Killer cell immunoglobulin-like receptors on NK cells: the how, 
where and why. International journal of immunogenetics 2008; 35(1): 1-8. 
2. Hollenbach JA, Nocedal I, Ladner MB, Single RM, Trachtenberg EA. Killer 
cell immunoglobulin-like receptor (KIR) gene content variation in the HGDP-
CEPH populations. Immunogenetics 2012; 64(10): 719-37. 
3. Sharma D, Bastard K, Guethlein LA, Norman PJ, Yawata N, Yawata M et 
al. Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 
3DL1 combine to form receptors with high, moderate, and no avidity for the 
complex of a peptide derived from HIV and HLA-A*2402. Journal of 
immunology 2009; 183(7): 4569-82. 
4. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles 
for HLA and KIR polymorphisms in natural killer cell repertoire selection and 
modulation of effector function. The Journal of experimental medicine 2006; 
203(3): 633-45. 
5. Gumperz JE, Valiante NM, Parham P, Lanier LL, Tyan D. Heterogeneous 
phenotypes of expression of the NKB1 natural killer cell class I receptor 
among individuals of different human histocompatibility leukocyte antigens 
types appear genetically regulated, but not linked to major histocompatibility 
complex haplotype. The Journal of experimental medicine 1996; 183(4): 
1817-27. 
6. Beziat V, Liu L, Malmberg JA, Ivarsson MA, Sohlberg E, Bjorklund AT et al. 
NK cell responses to cytomegalovirus infection lead to stable imprints in the 
human KIR repertoire and involve activating KIRs. Blood 2013. 
7. Carrington M, Martin MP, van Bergen J. KIR-HLA intercourse in HIV 
disease. Trends in microbiology 2008; 16(12): 620-7. 
8. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D et 
al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched 
haploidentical HSCT for pediatric patients: evaluation of the functional role 
of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 
113(13): 3119-29. 
K. Czaja                                                             PROJECT 3. 
79  
 
 
 
 
 
9. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R et al. 
Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C 
molecules in human natural killer cells. The Journal of experimental 
medicine 1995; 182(3): 875-84. 
10. David G, Morvan M, Gagne K, Kerdudou N, Willem C, Devys A et al. 
Discrimination between the main activating and inhibitory killer cell 
immunoglobulin-like receptor positive natural killer cell subsets using newly 
characterized monoclonal antibodies. Immunology 2009; 128(2): 172-84. 
11. Falco M, Romeo E, Marcenaro S, Martini S, Vitale M, Bottino C et al. 
Combined genotypic and phenotypic killer cell Ig-like receptor analyses 
reveal KIR2DL3 alleles displaying unexpected monoclonal antibody 
reactivity: identification of the amino acid residues critical for staining. 
Journal of immunology 2010; 185(1): 433-41. 
12. Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, Lanier LL. Cutting 
Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, 
encodes a DAP12-associated receptor expressed on NK cells that triggers 
NK cell activation. Journal of immunology 2007; 178(2): 647-51. 
13. VandenBussche CJ, Mulrooney TJ, Frazier WR, Dakshanamurthy S, Hurley 
CK. Dramatically reduced surface expression of NK cell receptor KIR2DS3 
is attributed to multiple residues throughout the molecule. Genes and 
immunity 2009; 10(2): 162-73. 
14. Trundley A, Frebel H, Jones D, Chang C, Trowsdale J. Allelic expression 
patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. 
European journal of immunology 2007; 37(3): 780-7. 
15.  Pyo CW, Guethlein LA, Vu Q, Wang R, Abi-Rached L, Norman PJ et al. 
Different patterns of evolution in the centromeric and telomeric regions of 
group A and B haplotypes of the human killer cell Ig-like receptor locus. 
PLoS One 2010; 5: e15115. 
16.  Della Chiesa M, Romeo E, Falco M, Balsamo M, Augugliaro R, Moretta L et 
al. Evidence that the KIR2DS5 gene codes for a surface receptor triggering 
natural killer cell function. Eur J Immunol 2008; 38: 2284–2289. 
17.  Steiner NK, Dakshanamurthy S, VandenBussche CJ, Hurley CK. 
Extracellular domain alterations impact surface expression of stimulatory 
natural killer cell receptor KIR2DS5. Immunogenetics 2008; 60: 655–667. 
K. Czaja                                                             PROJECT 3. 
80  
 
 
 
 
 
18.  Pittari G, Liu XR, Selvakumar A, Zhao Z, Merino E, Huse M et al. NK cell 
tolerance of self-specific activating receptor KIR2DS1 in individuals with 
cognate HLA-C2 ligand. J Immunol 2013; 190: 4650–4660. 
19.   Gourraud PA, Meenagh A, Cambon-Thomsen A, Middleton D. Linkage 
disequilibrium organization of the human KIR superlocus: implications for 
KIR data analyses. Immunogenetics 2010; 62: 729–740.  
20.   Alves LG, Rajalingam R, Canavez F. A novel real-time PCR method for KIR 
genotyping. Tissue Antigens 2009; 73: 188–191.  
21.  Fitzgerald DJ, Berger P, Schaffitzel C, Yamada K, Richmond TJ, Berger I. 
Protein complex expression by using multigene baculoviral vectors. Nat 
Methods 2006; 3: 1021–1032. 
22.  McErlean C, Gonzalez AA, Cunningham R, Meenagh A, Shovlin T, 
Middleton D. Differential RNA expression of KIR alleles. Immunogenetics 
2010; 62: 431–440. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
K. Czaja                                                             PROJECT 4. 
81  
 
 
 
 
 
 
PROJECT 4.  
 
Characterization of novel binding specificities of activating 
KIR2DS3 and KIR2DS5 to leukemic cell lines  !
K Czaja1*, A Gonzalez1*, L Schmied1, J Grählert1, I Burmann2, M Stern1
 !
1 Immunotherapy Laboratory, Department of Biomedicine, University Hospital Basel, Basel,    
  Switzerland 
2 Biozentrum, University of Basel, Basel, Switzerland 
 
* - These authors contributed equally.  
 
Manuscript 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
My contribution to work: 
Experimental design, performance of experiments, data analysis and 
interpretation, manuscript writing. 
K. Czaja                                                             PROJECT 4. 
82  
 
 
 
 
 
 
Abstract 
 
Numerous literature data suggest a general participation of B haplotype donor 
activating killer cell immunoglobulin-like receptors (KIR) in the elimination of 
residual leukemia after hematopoietic stem cell transplantation (HSCT). However, 
there is no direct evidence for binding of activating KIR to leukemia cells and these 
conclusions are drawn mainly from associations between donor KIR genotype and 
transplant outcome. High linkage disequilibrium between activating KIR genes 
makes it unlikely that further gene association studies will identify KIR genes 
responsible for the beneficial effects.  
 
We therefore biosynthesized soluble forms of activating KIRs as KIR-Fc 
conjugates and checked their binding to a panel of leukemic cell lines. We also 
measured their binding affinities. Considering the binding to HLA class I molecules 
of inhibitory KIR, we evaluated if activating KIR share the specificity. Moreover, we 
undertook a trial to confirm the function of activating KIRs by expressing them on 
NK cell line – NKL, which were destined for functional assays. Finally, we checked 
functional consequences of binding using assays with primary NK cells.  
 
We detected binding of KIR2DS3-Fc and KIR2DS5-Fc conjugate to an unknown 
ligand on the surface of HLA class I-deficient K562 cell line as well as KIR2DS3-Fc 
and KIR2DS5-Fc to HLA class I ligands on the surface of HEL and Namalwa cells. 
Binding was independent of HLA-C subgroups, and relatively weak when 
compared to inhibitory KIR receptor. The functional assays of KIR2DS5 positive 
subpopulation on primary NK cells against K562 cell line demonstrated a 
moderate input of that receptor in target cell killing. 
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Introduction 
 
The function of the NK cells is regulated by surface receptors, among which the 
killer cell immunoglobulin-like r eceptor (KIR) family is one of most important [1- 3]. 
This group consists of inhibitory and activating members, and therefore activation 
of NK cells is a result of a balance of signals derived from receptors with opposing 
function. 
Inhibitory KIRs recognize ligands among HLA class I molecules. For 
example, KIR2DL1 recognizes HLA-C molecules defined as subgroup C2. In 
contrast, KIR2DL2 and KIR2DL3 bind in general HLA-C (C1) epitopes [4-7]. Based 
on the high structural similarity, it could be expected that their activating 
counterparts exhibit similar binding preferences. This is the case for the 
KIR2DL1/DS1 receptor pair, in which the HLA-binding residues are conserved, 
enabling KIR2DS1 to bind HLA-C (C2) [8]. Binding of KIR2DS1 to HLA-C2 was 
confirmed functionally using cellular experiments [9, 10]. However, for the other 
activating KIRs - except for KIR2DS2, possibly binding to HLA-C (C1 subgroup) 
[11] - only for KIR2DS4 binding to some HLA-A and HLA-C subtypes was 
demonstrated using HLA-coated beads [12, 13]. Specificities of remaining 
activating KIRs are unknown. Despite this, HLA molecules are plausible 
candidates as ligands to the remaining activating KIR. Arguing in favor of that 
theory is the simultaneous evolutionary emergence of HLA-C accompanied by 
lineage III KIR expansion in primates [14, 15]. Also, in cases where the interaction 
is proven for both inhibitory and activating KIRs, the domains responsible for 
contact with HLA class I molecules are highly similar [6, 8]. The lack of a 
detectable binding of most activating KIR in previously reported experiments in the 
published literature may be due to allelic polymorphism of KIR genes or may be 
due to modulation of binding properties by peptides presented on HLA. The latter 
was extensively demonstrated for the interactions between KIR2DL1 and HLA-
Cw4 and also between KIR2DL2 and HLA-Cw3, which are modified by substitution 
of amino acids in position 7 and 8 (P7 and P8) of presented peptides [16, 17]. A 
similar example comes from studies on the influence of Epstein-Barr Virus (EBV) 
infection on KIR2DL1/DS1 binding, which shifts binding affinity from KIR2DL1 to 
KIR2DS1 [18]. Alternatively, it was also shown that KIR2DS4 binds an unknown 
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ligand on melanoma cell lines devoid of HLA expression; and that KIR3DL2 binds 
CpG oligodeoxynucleotides causing the internalization of the complex into Toll-like 
Receptor 9 (TLR9) containing endosomes [19, 20]. Hence, KIRs are also 
potentially able to bind non-HLA ligands. 
The KIR genes segregate as haplotypes containing combinations of 
inhibitory and activating KIRs. These haplotypes are divided according to 
presence of one or more activating KIRs into haplotypes A or B, respectively. 
Hence, the haplotype A contains mostly inhibitory KIRs with one (KIR2DS4) or no 
activating KIR, whereas B haplotypes carry additional (mostly activating) KIR 
genes [21, 22]. Retrospective studies have demonstrated that patients suffering 
from acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic 
myeloid leukemia and plasma cell myeloma (PCM) receiving hematopoietic stem 
cell transplantation from donors carrying B haplotypes exhibit reduced rates of 
disease relapse [23-28]. 
In this study we produced activating KIR-Fc conjugates in order to screen 
panels of malignant cell lines in a search for their ligands and check the interaction 
strength. Antibody blocking assessed whether ligands belong to group of HLA 
class I molecules. The function of receptors was evaluated by using primary NK 
cells. 
 
Materials and Methods 
 
Production of recombinant KIR-Fc fusion proteins 
 
Baculoviral constructs encoding the ectodomains of 2DS1, 2DS2, 2DS3, 2DS4, 
and 2DS5 in frame with the CH2 and CH3 domains of human IgG1 (Fc region) 
were kindly provided by P. Parham (Stanford University, USA). As revealed by 
sequencing, these activating KIR alleles were the most prevalent (KIR2DS1*002, 
KIR2DS2*001, KIR2DS3*001, KIR2DS4*001, KIR2DS5*002 and KIR3DS1*013). 
The KIR-Fc proteins were produced according the same scheme as previously 
described [29]. Briefly, the constructs were subcloned into pFL [30] and 
transfected by electroporation into packaging DH10EMBacYFP cells to obtain 
bacmid DNA. After confirming integrity and frame by sequencing, 2 µg of bacmid 
DNA was transfected with Cellfectin II (Invitrogen, Carlsbad, CA, USA) into Sf21 
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cells to obtain baculovirus supernatant V0. Two rounds of amplification followed to 
ensure high titer virus supernatants (V2), which were then used for recombinant 
protein production in protein-free culture medium (Insect-XPRESS protein-free 
insect cell medium with L-glutamine, Lonza, Verviers, Belgium) at 27°C. KIR-
fusion proteins were purified by protein A-sepharose affinity chromatography and 
analyzed by polyacrylamide gel electrophoresis. Their specificity was confirmed by 
blocking experiments as previously shown [29]. The concentration was assessed 
basing on absorbance at 280 nm by Nanodrop 2000 UV-Vis Spectrophotometer 
(Thermo Scientific, Rockford, IL, USA) and after its correction by molar extinction 
coefficient. 
 
Antigen coated bead screening of KIR-Fc fusions binding specificity 
 
The screening of KIR-Fc conjugates binding to a broad panel of HLA antigens was 
performed by the FlowPRA Specific Antibody Detection Test (One Lambda, 
Canoga Park, CA, USA) on the Luminex 200 (Luminex, Austin, TX, USA) platform 
as previously described [31, 32]. In short, the beads coated by HLA antigens 
derived from EBV-transformed human B-cell lines were incubated with KIR-Fc 
conjugates in concentrations of 10 µg/ml, 50 µg/ml or 200 µg/ml for 30 min. at 
room temperature. Beads were washed and incubated FITC-conjugated anti-
human IgG, washed again and destined for measurement [33]. 
 
Generation of activating KIR expressing NKL cell lines 
 
The NKL cell line was transduced by a retroviral transduction system and 
maintained in culture as described in material and methods section in Project 3. 
The test of functionality of the expressed receptors is described in functional assay 
section of that manuscript. 
 
Cell lines and PBMCs 
 
All human leukemic cell lines were a kind gift from A. Wodnar-Filipowicz 
(Department of Biomedicine, University Hospital Basel, Basel, Switzerland) and 
are summarized in Table.1. Their hematopoietic origin and viral infection status 
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information comes from the CABRI database (www.cabri.org). The lymphoblastoid 
cell lines BM21 and SPL were purchased from EMBL-EBI, IPD-IMGT/HLA cell 
bank and considering their HLA class I phenotype were used as KIR2DS1-Fc 
binding controls. All the cell lines were cultured with RPMI 1640 medium (Gibco, 
Paisley, UK) enriched with 10% fetal bovine serum (Sigma-Aldrich, Steinheim, 
Germany) and Penicillin (1000 U/ml)/Streptomycin (1000 µg/ml) (Gibco). Healthy 
donor buffy coats were collected in under an ethical committee approved protocol. 
Peripheral blood mononuclear cells (PBMC) were isolated by Lymphoprep (Axis 
Shield PoC AS, Oslo, Norway) gradient and frozen. 
 
Genotyping 
 
KIR genotype was assessed using sequence-specific primer PCR [34]. Known 
ligands for activating KIR2DS1 were typed by PCR-sequence-specific primer 
(HLA-C1 group versus HLA-C2 group) [35]. Four digit HLA genotyping was 
performed by Jean Villard (Immunology and Transplantation Unit, University 
Hospital Geneva, Geneva, Switzerland). 
 
Flow cytometry 
 
As previously mentioned the anti-KIR antibodies were used to evaluate of KIR-Fc 
conjugate integrity (existence of epitopes recognized by their corresponding 
antibodies). These KIR-Fc conjugates were incubated with the following antibodies 
prior to adding them to KIR expressing NKL cell line: anti-KIR2DL1/DS1/DS3/DS5 
(clone HP-MA4, Biolegend), anti-KIR2DL1/DS3/DS5 (clone 143211, R&D 
Systems, Minneapolis, MN, USA), anti-KIR2DL2/DS2/DL3 (clone DX27, 
Biolegend, San Diego, CA, USA), anti-KIR2DS4 (clone FES172, Beckman 
Coulter, Brea, CA, USA), and anti-KIR2D (clone NKVFS1, Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany), were all PE-labeled and used in dilution 1:50. 
Depletion of antibodies by KIR-Fc conjugates and lack of their binding to KIR 
expressing NKL the same receptor as applied soluble form confirmed the quality. 
In order to test binding of activating KIR-Fc conjugates to lymphoblastoid or 
leukemic cell lines, KIR-Fc at a concentration of 50 µg/ml were pre-incubated for 
20 min. at 4°C in the dark with the PE-conjugated goat anti-human IgG (One 
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Lambda) at 1:100 dilution. Meanwhile, cells (105 per single staining) were washed 
twice with FACS buffer (2% FCS in PBS) in 96 U-bottom well Falcon plates 
(Becton Dickinson, Franklin Lakes, NJ, USA). Afterwards, the cells were incubated 
for 30 min. at 4°C in FACS buffer in the dark with labeled KIR-Fc conjugates, 
washed twice, and stained with a viability dye (Sytox blue, Invitrogen, Carlsbad, 
CA) in dilution of 1:20000. Additional staining with the PE-conjugated goat anti-
human IgG (without KIR-Fc) was performed as control of unspecific binding of the 
secondary antibody. Since the KIRs are highly homologous, they constituted 
isotype controls to each other and differences in their binding guarantee the 
interaction via KIR domains, rather than via IgG-Fc. For additional confirmation of 
KIR-Fc binding specificity, KIR-Fc conjugates were biotinylated by Lightning-Link 
Type A Biotin Antibody Labeling Kit (Novus Biological, Cambridge Science Park, 
Cambridge, UK) according to the manufacturer’s manual, added to target cell 
lines, which were pre-incubated with KIR-Fc blocking reagent in dilution 1:20 for 
20 min. in 4°C, and detected by conjugate of streptavidin-PE (Southernbiotech, 
Birmingham, UK) in 1:50 dilution. 
For primary NK cells functional assays the flow cytometric sequential 
staining according materials and methods section of Project 3. was performed. As 
degranulation marker anti-CD107a-V450 antibody (BD Biosciences) was applied. 
The HLA class I expression on cell lines was evaluated by PE-labeled anti- 
HLA class I antibody (W6/32, Biolegend). In blocking assays, the incubation with 
unlabeled anti-HLA class I antibody (W6/32, Biolegend) at a concentration 50 
µg/ml for 30 min. at 4°C and two washes with FACS buffer prior to incubation with 
KIR-Fc conjugated, as well as anti-HLA-C antibody (DT9) at the same 
concentration received as a kind gift from R. Apps (Institute of Pharmacology and 
Physiology, University of Bristol, Bristol, UK) were applied. All analyzes were 
performed on a Cyan ADP Beckman-Coulter flow cytometer (Beckman Coulter). 
FACS plots were prepared with FlowJo software v. 9.4. 
 
Functional assays 
 
The functionality of activating KIRs in NKL cell line was determined by redirected 
cytotoxicity chromium release assay using as target cells the mouse mastocytoma 
cell line expressing FcγR receptor as earlier mentioned [13]. Two million target 
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cells were first incubated for 1 hour in 37°C with 200 µCi of radioactive chromium 
(51Cr isotope, Hartmann Analytic GmbH, Braunschweig, Germany) in 400 ul of 
RPMI medium. Afterwards, these cells were washed and incubated with unlabeled 
anti-panKIR2D antibody (NKVFS1, Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany) at a concentration of 1 mg/ml for 30 min. in 4°C, mixed with respective 
effector cells in effector:target (E/T) ratios 40:1, 20:1, 10:1 and 5:1, and incubated 
for 4 hours in 37°C in U-bottom 96-well plate. Total reaction volume was 200 ul. All 
samples were analyzed in triplicates. The efficacy of target cell lysis by effector 
cells was proportional to released radioactive chromium in 50 ul of medium 
containing released radioactive chromium, transferred to LumaPlate-96 
(PerkinElmer, Waltham, MA, USA), dried overnight and measured by Top Count 
NXT (PerkinElmer) microplate scintillation and luminescence counter. Total lysis 
was calculated in percentage using the formula: (specific release - spontaneous 
release)/(total release - spontaneous release) × 100. 
Further functional assays used the 721.221, 721.221C1 and 721.221C2 cell 
lines as target cell with additional application of KIR-blocking antibodies anti- 
KIR2DL1/DS1 (EB6b, Beckman Coulter, Brea, CA, USA) and anti-panKIR2D 
antibodies. Due to use of primary NK cells in functional assays checking functional 
consequences of activating KIR binding to a target cell, degranulation was 
evaluated by assessment of CD107a as previously recommended [36]. E/T ratio 
was low (40:1) in order to avoid maximal cytotoxicity effect and exhaustion of 
effector cells. The assay was carried out for 6 hours after mixing the cells, from 
which after 1 hour brefeldin A (Biolegend) in ratio 1:1000 was added. 
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Cell line Origin or leukemia type  EBV status 
697 Acute lymphoblastic leukemia (cALL) (B-cells) neg 
721.221 B-cell lymphoma pos 
721.221C2 B-cell lymphoma pos 
AML-193 Acute monocytic leukemia AML (FAB M5) neg 
BM21 Lymphoblastoid cell line (B-cells) pos 
BV-173 Chronic myeloid leukemia (Pre-B CML) neg 
Daudi Burkitt lymphoma (B-cells) pos 
DOHH2 Non-Hodgkin Lymphoma (B-cell) pos 
HEL Erythroid leukemia (monocyte-macrophage AML M6) neg 
HL60 Acute myeloid leukemia (FAB M2) neg 
Jiyoye Burkitt lymphoma (B-cells) pos 
Jurkat Acute lymphoblastic leukemia ALL (T-lymphocytes) neg 
K562 Chronic (erythrocytic-megakariocytic) leukemia CML neg 
Kasumi-1 Acute myeloid leukemia AML (FAB M2) neg 
MOLM13 Acute myeloid leukemia AML (FAB-M5a) neg 
Namalwa Burkitt lymphoma (B-cells) pos 
NB-4 Acute promyelocytic leukemia APL (FAB M3) neg 
Raji Burkitt lymphoma (B-cells) pos 
REH Acute lymphoblastic leukemia (pre-B ALL) neg 
SD-1 Acute lymphoblastic leukemia (pre-B ALL) pos 
SUP-B15 Acute lymphoblastic leukemia (pre-B ALL) neg 
SPL Lymphoblastoid cell line (B-cells) pos 
THP-1 Acute monocytic leukemia AML (monocytes) neg 
U937 Hystiocytic leukemia (monocytes) neg 
Table 1. Lymphoblastoid or leukemic cell lines used for KIR-Fc binding screening. 
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Results 
 
Control assays confirm the KIR2DS1, but neither KIR2DS2 nor KIR2DS4 
specificity 
 
After production of activating KIR-Fc conjugates, their specificity was checked 
using different methods. Using the previously described depletion assay, binding 
of anti-KIR antibodies to KIRs expressed on cell lines was abolished by pre-
incubation with saturating amounts of KIR-Fc conjugates [29]. All conjugates 
showed the expected specificity (data not shown). 
Since there exists literature data concerning ligands for KIR2DS1, KIR2DS2 
[9-11, 18, 37, 38] and KIR2DS4 (HLA-A*1102, -C*0501, -C*1601 and -C*0202) 
[13], we next compared the binding of those activating KIR-Fc to HLA-bearing 
beads with existing published data [31, 32]. The working concentration of 
conjugates was optimized and set up to 50 µg/ml. The screening was carried out 
with a set of beads coated with a broad panel of HLA class I allotypes allowing to 
dissect precisely the binding specificity towards HLA-A, -B, and -C molecules. As 
expected, the binding of KIR2DS1-Fc to molecules from HLA-C2 subgroup was 
observed (Figure 1), but in contrast to previous data [11, 13], no binding of 
KIR2DS4 to HLA-A*1102, HLA-C*0202, HLA-C*0501 and HLA-C*1601 was 
detected. In general, no activating KIR conjugates exhibited binding to HLA-A or 
HLA-B molecules (data not shown). 
Next, we tested KIR-Fc conjugate specificity by assessing binding to cell 
lines and primary cells. First, EBV-positive lymphoblastoid cell lines of known HLA 
configuration were used. Based on previous results, the KIR2DS1-Fc conjugate 
was tested in the binding assay with cell lines expressing a KIR2DS1 ligand 
(BM21, C2/C2) or devoid of a ligand (SPL, C1/C1). As shown in Figure 2A, strong 
binding of KIR2DS1-Fc conjugate to the BM21 cell line was noted, whereas no 
interaction with the SPL cell line was seen. The same result was obtained applying 
the HLA negative 721.221 cell line transfected to express single HLA-C1 and HLA-
C2 subgroup antigens (data not shown). Finally, weak binding was also detected 
to healthy donor peripheral mononuclear cells, if cells were derived from a donor 
carrying the HLA-C2 specificity (Figure 2B). 
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Further screening reveals new binding capabilities of activating KIRs 
 
Based on literature data indicating an advantage in leukemia-free survival in AML 
patients receiving allogeneic hematopoietic stem cell transplantation from a donor 
carrying activating KIRs [23], we next screened twenty leukemia cell lines with 
KIR-Fc conjugates. The cell lines included in our studies were diverse in terms of 
cell type, their development stage, type of leukemia, as well as expression of HLA 
molecules on their surface and EBV-infection status (Table 1). The screening 
revealed binding of both KIR2DS3-Fc and KIR2DS5-Fc conjugates to K562, HEL 
and Namalwa cell lines, but not the others (Figure 2C). The selective binding of 
only some, but not all KIR-Fc suggests specificity. To confirm that, KIR-Fc 
conjugates were biotinylated and added to target cells, which were earlier 
incubated with FcR blocking reagent. The binding detection was made by 
streptavidin-PE conjugates (Figure 3). 
 
The KIR-Fc conjugates exhibit rather weak binding affinity 
 
We next assessed binding affinity of activating KIR-Fc conjugates. Inhibitory KIRs 
demonstrate a broad range of affinity with Kd values between 10 nM to 1 µM [39], 
while the Kd of the KIR2DS1 to HLA-Cw4 was estimated to be 30 µM [9]. That is in 
accordance to regulatory mechanisms of NK cells, where affinity of activating KIRs 
should be equal or lower than that of inhibitory counterparts in physiologic 
conditions. Therefore, the mentioned values were a reference for our 
measurements. We performed flowcytometric binding assays of KIR-Fc 
conjugates to target cells in serial dilutions. Based on median fluorescence 
intensity (MFI), with highest values corresponding to saturation, we estimated the 
following Kd values: 0.8 µM, 5.0 µM and 7.0 µM at room temperature for KIR2DS1-
Fc (BM21 cells), KIR2DS3-Fc and KIR2DS5-Fc (HEL and Namalwa cells) 
respectively taking into account their 102 kDa molecular mass (Figure 4). The Kd 
value of KIR2DS3-Fc and KIR2DS5-Fc conjugates binding to K562 cell line was 
estimated to approximate 10 µM for both of them (data not shown). 
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Figure 1. Binding of human KIR2DS-Fc conjugates (KIR2DS1-Fc, KIR2DS2-Fc, KIR2DS3-Fc, 
KIR2DS4-Fc and KIR2DS5-Fc) to HLA-C (C1 and C2) coated beads presented as trimmed mean. 
NC - negative control, PC – positive control. 
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Figure 2. A) Binding of KIR2DS-Fc conjugates (KIR2DS1-Fc, KIR2DS2-Fc, KIR2DS3-Fc, 
KIR2DS4-Fc and KIR2DS5-Fc) to EBV-positive lymphoblastoid SPL (C1/C1) and BM21 (C2/C2) 
cell lines. B) Binding of KIR2DS1-Fc to PBMC from donors being either C1/C1 homozygote (upper 
panel) or C2/C2 homozygote (lower panel). C) Binding of KIR2DS-Fc conjugates (KIR2DS1-Fc, 
KIR2DS2-Fc, KIR2DS3-Fc, KIR2DS4-Fc and KIR2DS5-Fc) to leukemic cell lines (K562, HEL, 
Namalwa). In all cases the KIR2DS-Fc binding is represented by black solid line and secondary 
antibody alone binding is presented by gray filled histograms. 
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Figure 3. Binding specificity test with biotinylated KIR2DS5-Fc to K562 (left panel) and Namalwa 
(right panel) cells. The continuous line shows the binding of only KIR2DS5-Fc conjugate, dashed 
line depicts the binding of KIR2DS5-Fc conjugate after application of FcR blocking reagent and 
gray filled histograms illustrates the binding of secondary goat anti-human IgG antibody only. 
 
 
 
 
 
 
 
Figure 4. Binding strength of KIR2DS1-Fc (left panel), KIR2DS3-Fc (middle panel) and KIR2DS5-
Fc (right panel) conjugates assessed measuring the median fluorescence intensity (MFI) of 
respective KIR-Fc conjugates by flow cytometry in series of dilution (different molar 
concentrations). 
 
W6/32 antibody blocks the binding of KIR2DS3-Fc and KIR2DS5-Fc to HEL 
and Namalwa cell lines 
 
The interaction of inhibitory KIRs with HLA class I molecules and the high 
structural similarity of KIRs suggests that some HLA class I molecules alone or as 
complexes with peptides could be potential ligands for activating KIRs. Therefore, 
inhibition of KIR-Fc conjugate binding by pre-incubation with anti-HLA-A,-B,-C 
(clone W6/32) and anti-HLA-C (clone DT9) antibodies was carried out. Binding of 
the KIR2DS1-Fc conjugate to HLA-C2 on the BM21 cell line was only slightly 
reduced by W6/32 antibody (Figure 5A, upper panel). Similarly, the DT9 antibody 
did not block the interaction of both KIR2DS1-Fc conjugates (Figure 5A, lower 
panel). In contrast, the W6/32 antibody totally abolished the binding of KIR2DS3-
Fc (data not shown) and KIR2DS5-Fc to the HEL and Namalwa cell lines (Figure 
5B). The DT9 antibody did not interfere with the interaction of the KIR2DS3-Fc 
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(data not shown) KIR2DS5-Fc conjugate with both leukemic cell lines (Figure 5B).  
 
Killing of KIR2DS5-binding and KIR2DS5 non-binding cell lines by KIR2DS5 
positive primary NK cells  
 
Functional consequences of a cell ligand binding to KIR2DS5-Fc may be an 
increased capacity for NK cell activation and elimination of leukemic cells by 
corresponding receptor. Therefore, we performed a functional assay applying the 
cross-reactivity staining method (described in materials and methods section of 
Project 3). This would allow us to evaluate differences in degranulation in 
KIR2DS5+ primary NK cells against K562 (KIR2DS5-staining) or 721.221 (non-
staining) cell lines. Both cell lines are devoid of HLA expression on their surface, 
so no blocking effect from interaction with inhibitory KIRs is likely. We compared 
relative degranulation of KIR2DL1-/S1-/S5-, KIR2DL1+, KIR2DS1+/DS5+ and 
KIR2DS5+ NK cell subpopulation in donors homozygous for HLA-C2. As expected 
due to licensing, the KIR2DL1-/S1-/S5- NK cell subpopulation degranulated less 
than KIR2DL1+ NK cells (Figure 6A) but more strongly than KIR2DS1+S5+ NK 
cells (Figure 6B). In turn, KIR2DS5+ NK cell subpopulation degranulated at a 
similar level as KIR2DL1-/S1-/S5- NK cell subpopulation against K562 cells, but 
significantly less against 721.221 cells (Figure 6C). That may suggest an input of 
KIR2DS5 receptor in NK cell activity and its functionality. 
 
Functionality test of single activating KIR expressing NKL cell lines 
 
Single activating KIR-transduced NKL cells would be a useful tool to study the 
function of aKIRs. Activating KIRs were therefore expressed on the surface of NKL 
cells by retroviral transduction. The functionality of expressed receptors was tested 
by a redirected cytotoxicity assay against mouse P815 cells. As shown in Figure 
7A (left panel), the NKL cells do not lyse P815. NKL transfected with KIR2DS1 
lysed P815 in the presence of a redirecting antibody (Figure 7A, right panel). 
Similar data were obtained for the other single activating KIR expressing NKL 
cells, except for NKL2DS3, which showed rather weak and intracellular expression 
of the receptor (data not shown). This confirmed the presence and functionality of 
all cellular elements needed for signaling and degranulation. 
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Figure 5. Histograms show influence of anti-HLA-A,B,C (W6/32) antibody (upper row) and anti-
HLA-C (DT9) antibody (lower row) on binding: A) of KIR2DS1-Fc (left side) to a ligand on the 
surface of the BM21cell line and B) of KIR2DS5-Fc to a ligand on the surfaces of Namalwa (left 
side) and HEL (right side) cell lines. In all panels continuous line shows the binding of only 
KIR2DS-Fc conjugate, dashed line depicts the binding of KIR2DS-Fc conjugate after antibody 
blocking and gray histograms illustrates the binding of secondary goat anti-human IgG antibody 
only. 
 
The use of single activating KIR expressing NKL cells against P815 cell line 
is, however, a very artificial system. Confirmation in another assay is necessary. 
Therefore killing assays of NKL2DS1 and NKL2DS2 effector cells against 721.221 
cell lines expressing HLA-C1 or HLA-C2 ligands with and without KIR2L1/DS1 
blocking antibody were performed (Figure 7B). In every case difference decrease 
of lysis was observed in the presence of antibody. Similar results were obtained 
against K562 cells and no difference was visible, when anti-panKIR antibody was 
applied (data not shown). This suggests that reduced lysis was rather due to 
depletion of effector cells than due to blocking of an activating interaction. In 
summary, this system did not demonstrate functionality when used against 
physiological ligands and was therefore not used for confirmation of function of 
activating KIRs.  !
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Figure 6. Plots comparing degranulation of different populations of KIR2DL1+, KIR2DS1+ and 
KIR2DS5+ donors against K562 and 721.221 cell lines A) KIR2DL1-DS1-DS5- subpopulation to 
KIR2DL1+ in K562 (p<0.0001) and 721.221 (p=0.0006) cells B) KIR2DL1-DS1-DS5- subpopulation 
to KIR2DS1+/S5+ in K562 (p<0.0001) and 721.221 (p<0.0001) cells C) KIR2DL1-DS1-DS5- 
subpopulation to KIR2DS5+ in K562 (p<0.6182) and 721.221 (p=0.0476) cells. Statistical 
calculations were computed by paired t-Student test in 11 samples (n=11). !!!
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Figure 7. Plots comparing killing efficacy (percentage of lysis) of untransfected and activating KIR 
transfected NKL cell lines. Mean vales from triplicated wells are taken to evaluate target cells lysis 
in every E/T ratio (40:1, 20:1, 10:1, 5:1 in presence or absence of respective blocking antibodies A) 
NKL (left panel) and NKL2DS1 (right panel) effector cells against P815 cell lines.  B) NKL2DS1 
killing assay was performed against 721.221C1 (upper left panel) and 721.221C2 (upper right 
panel). NKL2DS2 killing assay was performed against 721.221C1 (lower left panel) and 721.221C2 
(lower right panel). 
 
 
 
 
 
 
 
 
 
 
 
%
"ly
si
s"
NKL"
!5#
5#
15#
25#
35#
45#
55#
40#:#1# 20#:#1# 10#:#1# 5#:#1#
!5#
5#
15#
25#
35#
45#
55#
40#:#1# 20#:#1# 10#:#1# 5#:#1#
no"Ab"
an/0panKIR2D"Ab"
NKL2DS1"
0#
20#
40#
60#
80#
40#:#1# 20#:#1# 10#:#1# 5#:#1#
0#
20#
40#
60#
80#
40#:#1# 20#:#1# 10#:#1# 5#:#1#
0#
20#
40#
60#
80#
40#:#1# 20#:#1# 10#:#1# 5#:#1#
0#
20#
40#
60#
80#
40#:#1# 20#:#1# 10#:#1# 5#:#1#
%
"ly
si
s"
no"Ab"
An/0KIR2DS1"Ab"
721.221C1" 721.221C2"
NKL2DS1"
NKL2DS2"
effector0target"ra/o"
effector0target"ra/o"
B 
A 
K. Czaja                                                             PROJECT 4. 
99  
 
 
 
 
 
 
Discussion 
 
The literature data indicate statistically clear advantages in terms of antiviral 
protection or antileukemic response in individuals carrying activating KIRs. The 
more precise explanation of mechanisms driving these beneficial effects could 
provide valuable information allowing for the prediction of antiviral reaction as well 
as optimal donor selection for bone marrow transplantation. For this reason we 
performed the search for ligands of activating KIRs aiming to evaluate more 
precisely their function. 
Similar to previous studies [13, 31] for KIR receptor binding screening we 
applied KIR-Fc conjugates of human origin and produced in insect cells in order to 
increase the yield. The binding of KIR2DS1-Fc to HLA-C (C2 subgroup) was 
confirmed, but no binding of KIR2DS2-Fc by use of HLA-coated beads was visible 
[40]. This is in contrast to recent data, where the recognition of HLA-C (C1 
subgroup) by that receptor was demonstrated on primary cells [11]. That 
inconsistency may be explained by differences in experimental systems: the 
interaction between HLA class I molecules and soluble forms of KIRs may not be 
equivalent to the situation when the molecules are placed on cellular membrane. 
Cellular assays might be better in visualization of low avidity interactions. In case 
of the KIR2DS4-Fc conjugate, the lack of binding shown previously [13] probably 
results from use of another HLA-beads kit, which may contain a different repertoire 
of peptides in HLA context, which would confirm the dependence of the interaction 
on a peptide [16]. Unfortunately, no exact source of those HLA molecules is given 
from manufacturer. Similarly, we could confirm the KIR2DS1-Fc binding on C2/C2 
lymphoblastoid cell line, but not the binding of KIR2DS2-Fc to SPL (C1/C1) cell 
line. The weak binding strength of KIR2DS1-Fc to C2/C2 primary cell line mirrors 
the physiological state where it has to be easily counterbalanced by inhibitory KIR, 
preventing the NK cell activation. 
In the following binding screening a new specificity of KIR2DS3-Fc and 
KIRDS5-Fc conjugates was discovered. Considering the intracellular physiological 
expression of the first [41], for its activity an additional factor causing 
externalization on the cellular membrane may be necessary. Taking into account 
the parameters characterizing these three binding cell lines like their origin, cell 
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type, and viral status (Table 1 and 2), all mentioned features could be excluded as 
binding influencers. HEL cells represent monocyte-macrophage AML and the 
binding confirms the role of activating KIRs against the disease in general [23, 26], 
but no binding was seen in case of the others AML cell lines. In case of the 
Namalwa cell line, there is no literature proof for interaction of KIR2DS5 receptor 
with Burkitt’s lymphoma blasts. Surprisingly, no binding of KIR2DS1-Fc was seen 
in any leukemic cell line. That may be caused by low expression of HLA by 
leukemic cells [42, 43] or peptide repertoire change in malignant transformed cells. 
KIR2DS3-Fc and KIR2DS5-Fc binding to HLA class I negative K562 cell line 
suggests a ligand, which is structurally similar to HLA class I molecules. The 
potential candidates could be searched among HLA-related stress-induced 
molecules MICA and MICB or in ULBP protein family. That hypothesis requires 
further investigation. 
The studies of binding affinities of KIR-Fc conjugates indicated a 
micromolar (µM) range of Kd value, which is weaker than for inhibitory KIRs 
(range from 10 nM to 1,0 µM) [6, 18, 39] This may be expected as stronger 
binding of inhibitory receptors to a HLA molecule on a “healthy” cell possibly 
prevents interaction of activating receptors and triggering the killing by NK cells. 
That affinity may however depend on different factors – polymorphisms of KIR 
itself as well as HLA-presented peptide, if the potential ligand is an HLA member, 
and be shifted towards activating KIRs. 
 
Cell line A1 A2 B1 B2 C1 C2 
HEL 03:01 32:01 35:01 35:08 04:01 04:01 
Namalwa 03:01 68:02 07:02 49:01 07:01 07:02 
Table 2. HLA genotyping results of KIR2DS3-Fc and KIR2DS5-Fc binding cell lines. 
 
The blocking of interaction by W6/32 antibody abolishes only in a small part 
the interaction between KIR2DS1 to HLA. The crystal structure of the KIR-HLA 
interaction, however, clearly shows the KIR binding to HLA-C2 molecules and is 
dependent on positions 80 in the α1 groove from the upper side involving also 
contact with amino acids P7 and P8 of the peptide [16, 17, 21]. It is very probable 
that W6/32 does not constitute a steric hindrance for KIR2DS1-Fc binding. In 
contrast, the W6/32 antibody totally abolishes KIR2DS3-Fc and KIR2DS5-Fc 
binding to HEL and Namalwa cell lines, which confirms that HLA class I molecules 
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are their ligands [16, 18, 44]. The genotyping results and the difference in blocking 
effect by W6/32 and DT9 antibodies rather exclude binding of KIR2DS3-Fc and 
KIR2DS5-Fc to ligands from HLA-C group. The HEL and Namalwa cell lines share 
the same subtype of HLA-A (*03:01) molecule, but no binding to another cell line 
carrying it – WT47 (data not shown) excludes it as ligand itself. More probably, a 
combination of HLA-A or HLA-B molecules in complex with presented peptides 
creates their binding domains, as demonstrated by Fadda et al. [45]. The DT9 
antibody seems to bind to a location, which does not interfere with KIR binding 
epitopes. 
The use of the HLA class I negative K562 cell line [46] binding KIR2DS5-Fc 
on its surface makes it possible to evaluate the potential killing effect of KIR2DS5 
receptor in primary NK cells. The HLA-negative cell line 721.221 was used as a 
negative control. We detected a modest difference in reactivity of KIR2DS5- 
expressing NK cells against K562 and 721.221: degranulation of KIR2DS5+ cells 
was lower against 721.221 but not against K562, when compared to KIR2DL1- 
/DS1/DS5- cells. This may be indirect evidence for an activating interaction 
between KIR2DS5 and a ligand expressed on K562, but will need further study. 
Experiments using activating KIR transfectants in order to evaluate more 
precisely the function of receptors were not successful despite their high activity in 
redirected cytotoxicity assay. The reason for that may be relative low affinity of 
KIRs and overcoming of their function by receptors from other groups present on 
NKL cell line (e.g. 2B4, NKG2C, NKG2D etc.) blocking possible interactions. 
Collectively our data show new potential binding possibilities for activating 
KIRs within or outside of the HLA class I context. Additionally we demonstrate 
moderate modulation of NK cell activity by KIR2DS5 receptor. Further 
investigations including immunoprecipitation and mass-spectrometry in order to 
identify these ligands as well as further functional assay are necessary for 
prediction of possible KIR2DS5 receptor diagnostic or immunotherapeutic 
application. 
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FINAL DISCUSSION AND PERSPECTIVES !
In the last years, the significant contribution of KIR to the immune response of NK 
cells against viral infections and tumors became clear. The possibility to better 
predict outcome of malignant and infectious diseases by assessing KIR genotype 
and phenotype, and the promising immunotherapeutic potential of NK cells 
encourages deeper studies.  
 Strategies to predict therapeutic response in order to improve treatment 
efficacy and decrease costs are used more and more frequently. For example, the 
search for markers predicting immunologic responses in HIV infected patients 
undergoing HAART identified a subgroup of patients carrying CX3CR1-249I or 
CX3CR1-280M alleles with superior response [130]. Similarly, we investigated the 
possibility to screen for factors associated with progression to AIDS like: KIR, their 
HLA class I ligands and SNPs as potential predictors of control of viral replication 
after STI. We found a modest association of HLA-Bw4 with low viral loads after 
STI. This strategy might be expanded in the future, e.g. by including HLA-B alleles, 
and particular SNPs (HLA-C-35, HCP5, ZNRD1, CCR5 Δ32 and CCR2 V64I), 
CCR5 haplotypes and CCL3L1 copy number variation which have previously been 
used to distinguish long-term non-progressors, from progressors, or even rapid 
progressors [131]. If such an expanded panel would be useful in the setting of STI 
remains unresolved at this time.  
 Our further studies concerning an antiviral role of NK cells were directed 
towards their interaction with CMV. CMV was chosen as target pathogen, as 
previous studies have indicated that CMV infection influences NK cell phenotype 
[132]. Moreover, recent studies showed protection from CMV reactivation after 
kidney transplantation and after stem cell transplantation [102] in patients carrying 
activating KIRs [105]. In contrast to our study, which detected an influence of CMV 
infection on KIR repertoire only after in vitro challenge with the virus but not in 
resting NK cells, a similar study investigating a larger cohort identified changes 
also in resting NK cells between CMV seropositive and –seronegative donors 
[133]. The expansion of functional NK cell subsets expressing KIR2DL1 and 
KIR2DL3 in the presence of their cognate ligands triggered by co-cultivation with 
CMV-infected fibroblasts is possibly caused by dynamic changes in MHC class I 
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expression and substitution of presented peptide repertoire [134]. Presentation of 
viral peptides has been shown to decrease interaction affinity and NK cell 
inhibition provoking a “missing-self” effect. Similarly to the studies of Beziat et al. 
[133] we demonstrate increased NKG2C expression in response to CMV, 
suggesting possible synergy of NK cell surface molecules within an immunological 
synapse. The role of each component requires, however, further investigation. Our 
results confirm the potential role of KIR3DS1 receptor, belonging to the telomeric 
part of the KIR haplotype, in the response to CMV infection. In contrast to the 
protective role of KIR3DS1 in HIV, which occurs only in the presence of HLA-Bw4, 
we found no such association in our studies on CMV.  
 In order to better understand possible roles of activating KIRs, we created 
soluble forms of activating KIRs, and single activating KIR transduced cell lines. 
This allowed us to screen commercially available anti-KIR antibodies for cellular 
specificities. We found new specificities including KIR2DS3 and KIR2DS5, which 
we applied for a new method of flow cytometric analysis.   
 The binding of KIR2DS3-Fc and KIR2DS5-Fc conjugates to HEL and 
Namalwa cell lines, is inhibited by an anti-HLA class I antibody and HLA 
genotyping results strongly suggest HLA-A or HLA-B in complex with peptides as 
ligands. The important role of peptides in the KIR-HLA interaction was previously 
demonstrated for KIR2DL3 and HLA-Cw3 [135, 136]. Identification of peptides 
allowing KIR2DS3 and KIR2DS5 binding is currently ongoing.  
The KIR2DS5-Fc binding to the HLA deficient cell line K562 is similar to the 
previously reported binding of KIR2DS4 to melanoma cell lines [137]. 
Consequences of binding in vivo are difficult to predict. Our functional assay 
applying sequential antibody staining showed a tendency of higher response of 
KIR2DS5+ NK cells against K562 (KIR2DS5-Fc staining, blastic phase of chronic 
myeloid leukemia) than against 721.221 (KIR2DS5-Fc non-staining). Interestingly, 
a small retrospective study found a protective role of donor KIR2DS5 in reducing 
relapse after allogeneic HSCT for chronic myeloid leukemia [138].  ! In summary, our data suggest a high diagnostic potential of activating KIRs. 
The identification of their ligands could not only help in developing a more detailed 
understanding of their function, but also improve their predictive application. 
Similarly, the effect of KIRs in hematopoietic stem cell transplantation, in terms of 
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leukemia elimination and viral reactivation, as an immunotherapeutic tool is worthy 
of further investigation. !  !!!!!!!!!!!!!!!!!!!!!!!!
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